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ABSTRACT
Poor invasion of trophoblast cells in early pregnancy has been associated with 
preeclampsia and intrauterine growth restriction as well as other adverse pregnancy 
outcomes such as miscarriage, preterm birth and intrauterine death. Hypertensive 
disorders of pregnancy, including pre-eclampsia are one of the leading causes of 
maternal mortality in South Africa (Third report on Confidential Enquiries into Maternal 
Deaths in South Africa (2002-2004)) and the rest of the world.
The currently accepted mechanism underlying the development of preeclampsia 
implicates poor trophoblast invasion and inadequate transformation of the maternal 
spiral arteries. Despite extensive research in this area, the control of trophoblast 
invasion and early placental development remains poorly understood. A whole 
host of factors such as oxygen tension, activation of matrix metalloproteinases 
(MMPs), angiogenic factors (VEGF-A) and immunological factors such as TNF alpha, 
interleukins and TGFb have been shown to be involved in the control of trophoblast 
invasion. Our knowledge of the molecular details of pregnancy is unfortunately limited 
to in-vitro experiments and animal studies. Recently kisspeptins and their cognate 
receptor GPR-54 originally involved in tumour metastasis suppression and regulation 
of puberty, have been implicated in the inhibition of trophoblast invasion. Expression 
levels of kisspeptin and its receptor in trophoblast cells are highest in the first trimester, 
when control of trophoblast invasion is critical, and lower towards term.
The placental trophoblast invades maternal tissues so as to attach the conceptus and 
access the maternal vasculature for nutrient transport and gaseous exchange. In this 
process fetal trophoblast encounters various maternal cells (including stromal and 
immune cell components) and hence considerable cross-talk and immune tolerance 
has to be exercised at the interface between invading fetal trophoblast and native 
maternal cells of the placental bed. Understanding the expression of factors involved 
in invasion such as proteases and angiogenic factors across this maternal-fetal 
XXI
interface is thus crucial in comprehending pregnancy-related disorders.
The hypothesis raised in this study was that kisspeptin gene and protein expression, 
along with the  expression of metalloproteases and angiogenic factors, will be 
different across the maternal-fetal interface of normal and abnormal placentation 
(preeclampsia in particular). The expression levels of kisspeptin, its receptor GPR54, 
metalloproteinases and angiogenic factors were studied across the maternal-fetal 
interface of healthy and preeclamptic patients.  Real-time reverse transcriptase PCR 
(RT-PCR), immunohistochemistry and western blot analysis were utilized to study 
gene and protein expression of factors involved in cellular invasion (Kiss-1, GPR-
54, MMP-9) and angiogenesis (VEGF-A, VEGFR-1, VEGFR-2, PROK-1 and PROK-
1R)  in the placenta, placental bed and decidua parietalis of healthy pregnancies and 
pregnancies complicated by preeclampsia. In addition enzyme-linked immunosorbent 
assays were employed to investigate circulatory concentrations of kisspeptin, VEGF-A 
and PROK-1 in maternal and fetal sera.
In the maternal-fetal tissues of healthy pregnancies the expression of invasive genes 
Kiss1, GPR-54  and MMP9 were higher in the placenta compared to the placental bed 
and decidua parietalis. The expression of angiogenic ligand VEGF-A was highest in 
the placental bed and there was reciprocal expression of its receptors with VEGFR1 
most expressed in the placenta and  VEGFR2 in the placental bed. Conversely the 
expression of the angiogenic ligand PROK-1 and its receptor PROK1R were highest 
in the placenta.
Pregnancies complicated by preeclampsia demonstrated high placental kisspeptin 
protein expression in comparison to healthy pregnancies but there was no difference 
in GPR-54  expression across the maternal-fetal tissues of preeclamptic and healthy 
pregnancies. There was reciprocal suppression of mRNA expression of angiogenic 
ligands across maternal-fetal tissues of preeclamptic pregnancies with PROK-
XXII
1 suppressed in the placenta and VEGF-A in the placental bed. In addition, mean 
cord serum VEGF-A concentrations were significantly lower in preeclampsia when 
compared to healthy pregnancies. There was however no significant difference in 
mean maternal or cord serum PROK-1 concentrations between preeclamptic and 
healthy pregnancies. Furthermore placental stimulation with kisspeptin resulted in no 
difference in the mRNA expression of VEGF-A, VEGFR1 and VEGFR2 in both healthy 
and preeclamptic pregnancies.
To summarise, in healthy pregnancies, genes associated with trophoblast invasion 
were highly expressed in the placenta which could suggest fetal control of trophoblast 
invasive capacity. On the other hand, findings on angiogenic gene expression profiles 
suggest that angiogenesis may be regulated by two distinct pathways with the 
PROK1-PROK1R ligand-receptor pair  predominantly mediating fetal angiogenesis 
and VEGFA-VEGFR2 ligand-receptor pair facilitating maternal angiogenesis. In 
preeclamptic pregnancies increased kisspeptin expression in the fetal (placenta) 
and suppressed pro-angiogenic gene, (VEGF-A and Prokineticin-1) expression in 
maternal (placental bed) components of the interface respectively, is consistent with 
reduced trophoblast invasiveness and compromised angiogenesis and may represent 
a molecular mechanism that explains the development of preeclampsia. 
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2Chapter 1 General Introduction
1.1 Introduction 
Pregnancy is a cherished event in most communities across the world. Although for 
the most part pregnancies progress uneventfully, pregnancy-related complications 
occur in the form of miscarriage, preeclampsia, intrauterine growth restriction (IUGR), 
preterm birth and even intrauterine death. These complications contribute significantly 
to global maternal and perinatal morbidity and mortality particularly in the developing 
world (Moodley, 2011, Sanders, 1999). 
Hypertensive disorders of pregnancy include gestational hypertension, chronic 
hypertension with superimposed preeclampsia and preeclamsia. Preeclampsia is the 
leading cause of direct maternal deaths in South Africa and contributes significantly 
to adverse perinatal outcomes. This disorder is typified by development of new-onset 
proteinuria and hypertension after 20 weeks of pregnancy which is part of a systemic 
multi-organ endothelial dysfunction in the mother, with involvement in the brain 
(eclampsia, intracerebrovascular haemorrhage and posterior reversible encephalopathy 
syndrome), lungs (pulmonary oedema), heart (left ventricular dysfunction), kidneys 
(renal impairment and failure) (Cornelis et al., 2011), liver (dysfunction or capsular 
rupture) and coagulation system (thrombocytopaenia and disseminated intravascular 
coagulopathy). The fetal sequelae include intrauterine growth restriction secondary 
to placental insufficiency, placental abruption, preterm birth and intrauterine demise. 
Despite extensive research focusing on this condition, the pathophysiology of 
preeclampsia still remains poorly understood. The global prevalence of preeclampsia 
ranges between two and eight  percent (Duley, 2009). 
Despite imprecise knowledge about the pathophysiology of pregnancy-related 
morbidity, it is generally acknowledged that abnormal placentation remains the 
foundation upon which pregnancy-related pathology develops (Khong and Brosens, 
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2011). Effective trophoblast invasion is influenced by molecular pathways involving 
cellular proliferation, invasion, expression of particular adhesion molecule profiles 
(Aplin, 1993, Arimoto-Ishida et al., 2009), evasion of maternal immune detection, 
elusion of apoptotic signals and stimulation of angiogenesis. Successful trophoblast 
cell populations constituting a healthy pregnancy manifest most of the above traits 
which allow deep invasion of maternal tissues and transformation of myometrial spiral 
arteries. Failure of transformation of spiral arteries is the definitive mutual pathway 
underlying most pregnancy-related pathologies as untransformed vessels (from high 
resistance low capacity to high capacity low resistance) are incapable of adequately 
providing for the enormous metabolic demands of pregnancy (Brosens, 2011, 
Espinoza et al., 2006).
It is widely accepted that normal placental development (placentation), which is the 
growth and development of the placenta and the accompanying development of 
the uterine capacity to supply blood required by the fetus, translates to healthy and 
successful pregnancy. Hence understanding the molecular mechanisms involved in 
normal placentation and what is perturbed in abnormal placental development is likely 
to result in appropriate prophylactic and therapeutic interventions. Such interventions 
would have a significant impact on global maternal and perinatal mortality in keeping 
with the objectives of the United Nations Millennium Development Goals (MDG) 4 
and 5, namely reduction in maternal mortality and improvement in childhood survival 
(Lalonde and McMullen, 2009).
Numerous factors impede our precise understanding of the aetiology of pregnancy-
related pathology such as preeclampsia, despite considerable financial and human 
resource investment in research. One such factor is our lack of precise knowledge about 
the molecular details involved in normal pregnancy, which makes comprehension of 
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pregnancy-related pathology more challenging. The other factor is that over the years 
the placenta rather than the placental bed has been the focus of investigation. The 
placental bed is a site of immense cross-talk between fetal trophoblast and maternal 
decidua (Herrler et al., 2003), and ultimately the location where transformation of the 
maternal spiral arteries occurs. 
This chapter introduces the placenta and the placental bed which are components 
of the core maternal-fetal interface, the various trophoblast cell populations and their 
respective roles in maternal invasion and spiral arterial transformation. In addition 
the ligands and receptors that are the subject of this thesis are also introduced, with 
kisspeptin and its receptor GPR-54  (also known as Kiss1R) primarily involved in the 
invasion pathway while VEGF-A, Prokineticin-1 or PROK-1 (also known as EG-VEGF) 
and their respective receptors VEGFR-1, VEGFR-2 and PROK1-R are involved in 
angiogenesis.
Chapter Two is a detailed description of the materials and methods utilized for gene 
and protein expression studies. Chapter Three focuses on the expression of the 
above-mentioned invasion and angiogenic factors across the maternal-fetal interface 
of healthy human pregnancies. Chapter Four compares the maternal-fetal expression 
of these ligands and receptors in healthy pregnancy and preeclampsia. Chapter Five 
explores the effect of placental kisspeptin stimulation on angiogenic ligand and receptor 
transcript expression in heathy and preeclamptic pregnancies. The final chapter is a 
general discussion with concluding remarks and proposed future prospective work.
1.2 The Placenta 
The embryonic origin of the placenta is the trophectoderm layer of the blastocyst. It is 
of paramount importance for gaseous exchange and nutrient transport from the mother 
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across to the fetus (Gude et al., 2004, Burton et al., 2001). In addition the placenta is 
crucial for anchoring the developing embryo to the maternal tissues. Healthy pregnancy 
and fetal development are therefore dependent upon normal placental formation and 
development (placentation). The placenta consists of primary, secondary and tertiary 
villous structures lined by the outermost multinucleated syncytiotrophoblast layer 
which is bathed in maternal blood (Figure 1.1). 
 
Villous capillary
vessels
Syncytiotrophoblast
Cytotrophoblast
Primary villus
Terminal villus
Maternal blood
Stem villus
Secondary villus
IVS
IVS
IVS
Figure 1.1 Coronal section of the placental villous tree bathed in the intervillous space 
(IVS), illustrating stem, primary, secondary and terminal villi. Insert shows magnification 
of a terminal villus lined by outermost syncytiotrophoblast layer (shown as green), inner 
cytotrophoblast cell layer (pink) and villous capillary vessels (orange and blue).
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Directly underlying the syncytiotrophoblast layer which is a true syncytium devoid 
of cellular boundaries, is the mononuclear cytotrophoblast cell layer with distinct 
cellular walls (Figure 1.2). The cytotrophoblast is the trophoblast stem cell with 
ability to differentiate into the overlying proliferative syncytiotrophoblast  layer which 
is responsible for gaseous exchange and nutrient transport or to cytotrophoblast 
columns which enter the invasive extravillous pathway. 
Intervillous space (IVS)
Villous mesenchyme
Cytotrophoblasts
Villous capillary vessels
Hofbauer cells (villous 
macrophages)
Cytotrophoblast Columns
Multinucleated syncytiotrophoblast cells
IVS
IVS
IVS
Figure 1.2 Sagittal section of the placental villus showing cytotrophoblast cells (pink) 
with distinct cellular walls. The villous cytotrophoblast can either differentiate into 
the outermost multinucleated syncytiotrophoblast cell layer (green) bathed in the 
intervillous space (IVS) or form cytotrophoblast columns (CC) which enter the invasive 
pathway. Within the villous mesenchyme (light yellow) lie villous capillary vessels (blue 
and orange), villous macrophages (Hofbauer cells) and other villous stromal cells. The 
nuclei are depicted in dark blue.
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The extravillous trophoblast (EVT) is key to invading the maternal uterine wall 
(decidua) resulting in anchorage of the conceptus to the mother and transformation 
of the maternal spiral arteries (Kam et al., 1999). Much research has focused on 
understanding factors responsible for which differentiation pathway cytotrophoblast 
cells ultimately take; proliferative or invasive (Sasagawa et al., 1996, Wright et al., 
2010, Xu et al., 2002, Caniggia et al., 2000, Genbacev et al., 1996).
Due to the crucial role the placenta plays in determining fetal health and pregnancy 
outcome, the study of the placenta (also known as placentology) is becoming 
increasingly important in addressing problems relating to maternal and child health. 
Furthermore, the association between abnormal placentation and development 
of diseases of adulthood such as late-onset diabetes and hypertension (placental 
programming), has made the detailed study of the placenta even more compelling than 
ever before. Placental programming, also known as developmental origins of health 
and disease (DOHaD) tenders an immense opportunity for the possible realisation 
of true adult preventive medicine in the coming decades. (Barker, 2012, Barker and 
Thornburg, 2013, Hanson and Gluckman, 2011). 
1.3 Maternal Decidua
The term decidua originates from “deciduous” trees which akin to menstrual shedding, 
loose their leaves in a seasonal manner.  Decidualisation of the endometrium 
commences in the mid-luteal phase of pregnancy secondary to post-ovulatory 
progesterone production. A rise in progesterone triggers morphological changes 
initially in the endometrial glandular epithelium with appearance of basal subnuclear 
vacuoles followed by an increase in stromal cell size and glycogen production in 
the endometrial stroma. In addition to glycogen, the decidual stromal cells secrete 
prolactin, growth factors (e.g fibroblast and epidermal growth factor), extracellular 
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matrix proteins (collagen, laminin and fibronectin) and insulin-like growth factor 
binding protein-1 (IGFBP-1) which are thought to enhance implantation. (Loke and 
King., 1995)
The glandular epithelial changes result in production of factors such as, mucin, glycogen 
and glycoproteins which traditionally have been thought to support the developing 
blastocyst prior to accessing maternal spiral arteries. The decidua however has also 
been thought to modulate invasion of EVT and thus prevent potentially catastrophic 
over-invasion of trophoblast cells. The main objective of decidualisation is to optimise 
embryo implantation and is thus accompanied by secretion of a whole host of factors 
including production of VEGF-A and expression of matrix proteases. (Pijnenborg et 
al., 2010)
The endometrial lining in pregnancy is known as the decidua. The decidua consists 
of the decidua basalis and capsularis which underlie the placenta (and are part of 
the placental bed) as well as the decidua parietalis which has no involvement in 
placentation (Figure 1.3)
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Coronal section of the uterus with placenta in situ
Inner 1/3 myometrium
Junctional zone
myometrium
Outer 2/3 myometrium
PB
DP
DB - Decidua basalis
DP - Decidua parietalis
PB - Placental Bed (Decidua basalis 
 and junctional zone myometrium
PL - Placenta
UC - Umbilical Cord
DP
UC
PL
PB
DB
Figure 1.3  Coronal section of the uterus with the placenta in situ illustrating the umbilical 
cord (UC) with  placenta. The placenta rests on the placental bed (PB) constituted by 
the decidua basalis (DB-green) and junctional zone myometrium (black). The junctional 
zone myometrium is part of the inner third of the myometrium (pink). The decidua 
parietalis (DP-yellow) has no involvement with the placentation.
1.3.1 The Placental Bed 
The placental bed consists of the decidua basalis, interstitial trophoblast and underlying 
myometrium with spiral arteries (Lyall, 2002). As extravillous trophoblast invades the 
decidua basalis, it interacts with collagen, as well as maternal stromal and immune cell 
components. The immune cell component of the maternal-fetal interface consists of 
decidual leukocytes, macrophages and decidual natural killer cells (dNKs) also known 
as uterine natural killer cells (uNKs). The maternal stroma consists of amongst others 
decidual fibroblasts, stromal cells, glandular tissue, vessels with vascular endothelial 
cells and collagen matrix. Although initially thought to limit trophoblast invasion by 
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eradicating invading EVT, uNK cells, unlike their peripheral counterparts (peripheral 
blood natural killer cells) exhibit no cytotoxic activity. Recent evidence suggests that 
uNK cells may be responsible for modulating maternal immune tolerance and spiral 
arterial transformation in conjunction with interstitial trophoblast (Williams et al., 2009). 
Additionally, uNK cells play a key role in trophoblast independent remodelling of spiral 
arteries (Gerretsen et al., 1983, Whitley and Cartwright, 2010).
1.3.2 Decidua Parietalis 
The decidua parietalis is the innermost uterine layer (endometrial layer) in pregnancy, 
has no overlying placenta and is devoid of trophoblast cells. It has no invading 
trophoblast nor transformed spiral arteries (Figure 1.3).
1.4 Trophoblast invasion and trophoblast populations
The progenitor of all trophoblast cells is the villous cytotrophoblast (vCT).  The vCT 
can either differentiate into proliferative syncitiotrophoblast (sTB) or give rise to 
invasive cytotrophoblast columns (Figure 1.2). The sTB is responsible for gaseous 
exchange and nutrient transport from the maternal intervillous space to the placental 
villous capillaries. On the other hand the cytotrophoblast columns represent the early 
stages of the invasive pathway. These columns subsequently give rise to the invasive 
extravillous trophoblast (EVT) cells (Huppertz, 2003). The EVT may either invade 
the maternal decidua and are then known as interstitial trophoblast or colonize the 
decidual and myometrial components of spiral arteries as endovascular trophoblasts 
(Kaufmann et al., 2003). It is endovascular trophoblasts that are thought to transform the 
maternal spiral arteries from high resistance low capacity structures to low resistance 
high capacity vessels capable of supporting a healthy pregnancy. It is, however, unclear 
whether the origin of endovascular trophoblast is from direct endovascular invasion of 
spiral arteries by trophoblast emanating from cytotrophoblast columns (inside out) or 
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from interstitial invasion of surrounding  perivascular trophoblast (outside in).
Invasion of trophoblast cells is highest in the first trimester of pregnancy when 
placentation is being established and only extends as far as the inner third of the 
myometrium (also known as the junctional zone myometrium). What stops invasion 
of trophoblast cells beyond the junctional zone myometrium remains largely unknown 
however both under-invasion and over-invasion have the potential for severe maternal 
as well as fetal morbidity and mortality. While the former is associated with intrauterine 
growth restriction and preeclampsia, the latter is thought to result in morbid placental 
adherence- placenta accreta, increta and percreta.The placenta cretas often result in 
poor placental separation at parturition leading to massive postpartum haemorrhage 
requiring hysterectomy (Belfort., 2010, Hannon et al., 2011, Laban et al., 2014). As 
morbid placental adherence was rare prior to the advent of caesarean deliveries, part 
of the pathophysiology likely involves dysfunctional decidual components along the 
uterine scar (Jauniaux and Jurkovic., 2012). 
As early as 1958, Robertson and Dixon studied the vascular changes in the placental 
beds of both normotensive and hypertensive pregnancies (Brosens et al., 1967, 
Robertson et al., 1967 a). They found that hypertensive pregnancies were characterized 
by lack of transformation of the maternal spiral arteries (Dixon and Robertson, 1958). 
This lack of spiral artery transformation was initially thought to be secondary to defective 
trophoblast invasion of maternal tissues in preeclamptic pregnancies. However, 
early spiral arteriolar changes in the junctional zone myometrium occur prior to the 
onset of trophoblast invasion (Brosens et al., 2002) and it is likely that immune cells 
(particularly uNK cells) within the maternal decidua play pivotal roles in spiral arterial 
transformation. Early vascular changes in the spiral arteries possibly commence with 
decidualisation of the endometrium in response to luteal phase hormonal changes 
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(Khong and Brosens, 2011).
A healthy pregnancy is therefore dependant upon successful invasion of the 
maternal tissues by fetal trophoblast cells in the early stages of pregnancy. Failure 
of this trophoblast invasion leads to poor remodelling of the maternal spiral arterial 
and development of conditions of placental malperfusion such as pre-eclampsia, 
intrauterine growth restriction, miscarriage (Ball et al., 2006) and preterm delivery.
The molecular mechanisms governing trophoblast invasion remain poorly understood 
and part of the difficulty is in the relative inaccessibility of the trophoblast-decidual 
interface  during pregnancy. The use of in-vitro models and animal studies have 
however facilitated some understanding of maternal-fetal  dialogue.
1.4.1 Factors affecting trophoblast invasion 
A whole host of factors have been implicated in the differentiation, proliferation and 
invasion of trophoblast cells. How deeply the trophoblast cells invade is a function of 
the balance between pro-invasive and anti-invasive factors present in the fetal and the 
maternal tissues at one time (Knofler, 2010). Amongst some of the key factors studied 
are oxygen tension, expression of proteases, angiogenic factors and genes involved 
in trophoblast proliferation and motility.
1.4.1.1 Oxygen tension 
Oxygen tension is likely the most important factor determining invasive capacity and 
affects cytotrophoblast differentiation and trophoblast invasion (Robins et al., 2005, 
Genbacev et al., 1996, James et al., 2006). Some studies have shown that under hypoxic 
conditions, cytotrophoblast stem cells favour a more invasive extravillous pathway 
with less expression of syncytin and human placental lactogen typically expressed by 
syncytiotrophoblasts (Robins et al. 2005). Others however have demonstrated elevated 
13
Chapter 1 General Introduction
expression of both Hypoxia Inducible Factor (HIF) and Transformation Growth Factor 
Beta 3 (TGF-b3) in early first trimester. HIF-1 is a heterodimer molecule constituted by 
HIF-1 alpha (HIF-1a) and HIF-1 beta (HIF-1β). HIF-1a is the constitutively expressed 
transcriptional factor responsible for cellular responses to low oxygen tension (Gultice 
et al., 2009). Under high oxygen conditions HIF-1a is inactivated by degradation and is 
thus unable to form the heterodimeric HIF (in conjunction with HIF-1β) responsible for 
binding to hypoxia response elements affecting cellular transcription. Transformation 
Growth Factor Beta 3 (TGF-b3) inhibits EVT differentiation and invasion (Caniggia 
et al., 2000) likely via suppression of metalloproteinase activity (Lash et al., 2005). 
Hence under hypoxic conditions there is increased expression of heterodimeric HIF-
1 and TGF-b3 favoring the proliferative rather than invasive pathway. A high oxygen 
environment is detrimental to early embryogenesis due to the generation of reactive 
oxygen species (ROS) to which the embryo is poorly adapted. Prior to 9 weeks 
gestation the embryo is protected from ROS by the plugging of spiral arteries by 
endovascular trophoblast. This vascular plugging results in reduced blood flow to the 
intervillous space which provides a lower oxygen environment for the growing fetus.
1.4.1.2 Protease expression 
For  trophoblast cells to invade maternal decidua they must first attach to extracellular 
matrix and then migrate by traction. Cells interact with extracellular matrix via 
expression of cell surface adhesion molecules, in particular intergrins.  The latter 
are transmembrane glycoproteins with extracellular and cytoplasmic domains and 
are constituted by various α and β subunits. The combination of the various α and 
β subunits determine which extracellular matrix (ECM) protein the cell will bind to. 
ECM proteins include amongst others, fibronectin, type I and IV collagen as well 
as laminin which forms an integral part of the villous basement membrane. (Loke 
and King., 1995). Villous trophoblast cells are known to express the α6β4 intergrin 
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(laminin receptor), which they progressively lose as they enter the invasive extravillous 
pathway. In contrast invasive interstitial trophoblast mostly express α5β1 intergrin, the 
fibronectin receptor which seems to be associated with cellular motility. 
There are two families of proteases that degrade extracellular matrix, the plasminogen 
activators and the metalloproteinases. The plasminogen activators, tissue Plasminogen 
Activator (tPA) and urokinase Plasminogen Activator (uPA) convert inactive plasminogen 
to active plasmin and are controlled by Plasminogen Activator Inhibitors-1, -2 and 
-3 (PAI-1,-2 and -3). Similarly the metalloproteinases are secreted as inactive pro-
enzymes and are classified into three sub-families depending on which substrates 
they mainly degrade. The Collagenases (MMP-1 and MMP-5) act on fibrillar collagens 
and cleave α-chains of type I, II and III collagens. The Gelatinases (MMP-2 and 
MMP-9) as their name suggests cleave gelatin which is denatured collagen, type IV 
(basement membrane) collagen and type V collagen. Lastly the Stromelysins (MMP-
3, MMP-7 and MMP-10) act on a broad range of substrates including proteoglycans, 
glycoproteins such as fibronectin and laminin as well as type IV collagen. The action of 
metalloproteinases is controlled by tissue inhibitors of metalloproteinases (TIMPs). Of 
the two broad families of matrix-degrading proteinases (i.e the plasminogen activators 
and the metalloproteinases), the latter have been shown to play a more significant role 
in trophoblast migration and invasion.
The ability of trophoblast cells to express proteases that digest extracellular matrix 
greatly enhances their invasiveness (Moll and Lane, 1990). In particular the invasion-
enhancing expression of gelatinases (MMPs) 2 and 9, and their membrane-type 
activators (membrane-type metalloproteinase-1; MT-MMP-1 (also known as MMP-
14)) have been extensively studied in the placenta (Bischof et al., 1995, Hurskainen 
et al., 1998, Isaka et al., 2003, Bjorn et al., 1997) and demonstrate a gestational age 
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dependent differential pattern of expression (Staun-Ram et al., 2004). On the other 
hand the expression of tissue inhibitors of metalloproteinases (TIMPs) by the maternal 
decidua down-regulates this invasive capacity (Xu et al., 2000, Anacker et al., 2011).  
1.4.1.3 Placental Hormones 
Gonadotrophin Releasing Hormone (GnRH) I and II are expressed in vCT and EVT and 
upregulate the expression of MMP-9 and MMP-2 in vitro (Liu et al., 2010). Similarly 
human chorionic gonadotrophin (hCG) upregulates MMP-2 expression via ERK and 
AKT signaling pathways (Prast et al., 2008). Placental growth factor  (PlGF) and 
Insulin-like Growth Factor II (IGF-II) likewise promote the invasive capacity of these 
cells. Insulin-like Growth Factor Binding Protein-4 (IGFBP-4) is exclusively expressed 
by the maternal decidua and is a potent inhibitor of IGF-II action by rendering it less 
bioavailable thus providing maternal inhibition to trophoblsst invasion. In contrast 
placentally expressed IGFBP-4 protease (also known as PAPP-A) cleaves IGFBP-4, 
increases bioavailable IGF-II and results in promotion of trophoblast invasion (Giudice 
et al., 2002).
1.4.1.4 Angiogenic factors
Vasculogenesis is the de novo formation of new blood vessels from haemangiogenic 
progenitor cells while angiogenesis is the development of new microvessels from 
existing vessels (Demir et al., 2007).In humans, placentation involves vasculogenesis 
from day 21 post-fertilization during formation of tertiary chorionic villi  and  angiogenesis 
from day 32 during continued chorionic growth  and neo-vascularization of the decidua 
(Kaufmann et al., 2004). The placenta develops by branching angiogenesis from day 
32 post-fertilisation to 24 weeks and by non-branching angiogenesis from 24weeks 
to term (Charnock-Jones et al., 2004).
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Vascular Endothelial Growth Factor (VEGF), previously known as vascular permeability 
factor (Senger et al., 1983) plays a pivotal role in angiogenesis. VEGF is a homodimeric 
glycoprotein of 45kDa which stimulates growth of vascular endothelial cells, promotes 
vascular  permeability, induces a powerful angiogenic response in vivo and is a 
potent mitogen. VEGF has various isoforms (VEGF-A, VEFG-B, VEGF-C, VEGF-D 
and VEGF-E) of which VEGF-A in particular is key in angiogenesis of placentation 
and pregnancy (Clark et al., 1998b). VEGF-A mediates its mitogenic and angiogenic 
effects by binding to three receptor tyrosine kinases (Ferrara et al., 2003). VEGF 
Receptor-2 (VEGFR-2) also known as the Kinase Domain Receptor (KDR) is the main 
mediator of the mitogenic, angiogenic and permeability-enhancing effects of VEGF. 
VEGF Receptor-1 (VEGFR-1) on the other hand is known as the “decoy receptor” as 
it scavenges off and reduces the amount of VEGF-A available to bind to VEGFR-2. 
VEGFR-1 is therefore anti-angiogenic. Lastly VEGFR-3 is involved in lymphangiogenesis 
(Ferrara et al., 2003). VEGF mRNA has been localized to cytotrophoblast columns 
and invading EVT(Charnock-Jones et al., 1994) while VEGFR-1 and VEGFR-2 mRNA 
expression has been localized to EVT and endothelial cells respectively (Clark et al., 
1996).VEGF promotes trophoblast invasion by stimulating the activity of proteases 
such as urokinase plasminogen activator (uPA) and MMP-9 (Anteby et al., 2004) .
Recently, Endocrine Gland Specific VEGF (EG-VEGF) also known as Prokineticin-
1(PROK-1) and its cognate receptor PROK1R have been characterized (LeCouter 
et al., 2001, Soga et al., 2002).  Similar to VEGF, EG-VEGF induces proliferation, 
migration and fenestration in capillary endothelial cells. Furthermore it also possesses 
a HIF binding site in its promoter and like VEGF its expression is induced by hypoxia. 
However unlike VEGF, its expression is restricted to steroidogenic organs like the 
ovary, testis, adrenal and the placenta and its action is specific to capillary endothelial 
cells derived from these endocrine glands. While VEGF mediates its action via receptor 
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tyrosine kinases, EG-VEGF does so through G-protein-coupled receptors (PROKR1 
and PROKR2). In the placenta the action of EG-VEGF is thought to be complementary 
to that of VEGF because, while VEGF is expressed in cytotrophoblast and EVT, EG-
VEGF is mainly expressed by syncytiotrophoblast (Hoffmann et al., 2006). In vitro, 
EG-VEGF expression is regulated by hypoxia (Hoffmann et al., 2006) and interestingly 
seems to suppress EVT migration, invasion and tube-like formation (Hoffmann et al., 
2009). Other important angiogenic role players affecting trophoblast invasion include 
placental growth factor, fibroblast growth factor and endoglin.
1.4.1.5 Kiss1 gene, kisspeptins and GPR-54
RF (R- Arginine, F- Phenylalanine) amides are a group of peptide hormones that have 
a common Arg-Phe-NH2 motif at their C-terminus and all bind to G protein-coupled 
receptors.  RFamides are involved in many processes throughout the body including 
inflammatory responses, control of food intake and development.  One major area 
where RFamides play a role is reproduction, involving two RFamides: Gonadotrophin 
Inhibitory Hormone (GnIH) and Kisspeptin.  Of the two, kisspeptin has been more 
widely characterized and it is this peptide that is the focus of this research project.
Kisspeptin was originally isolated as an anti-metastatic peptide from melanoma cells 
and was initially termed metastin(Lee et al., 1996). Kisspeptin is encoded by the Kiss1 
gene and is synthesized as a precursor protein of a 145amino acid polypeptide (Ohtaki 
et al., 2001). Posttranslational modification of the transcript results in four kisspeptins 
with 54 (metastin), 14, 13 and 10 amino acids which all include the essential carboxyl 
terminal 10 amino acids (Fig 1.4). 
The 10 amino-acid peptide (kisspeptin-10), YNWNSFGLRF-NH2 which ends with an 
RF-amide is sufficient to activate the receptor.
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Kisspeptins are the natural ligands of an orphan G-protein coupled receptor, GPR54 
(also known as Kiss1R or AXOR12)(Muir et al., 2001). The GPR54 receptor has a 396 
amino-acid open reading frame and is related to the galanin receptor family, although 
it does not bind galanin.
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Figure 1.4 The structure of the human kisspeptin pre-pro-protein (Kp-145) and its 
posttranslational products, kisspeptin 54, 14, 13 and 10. (Adapted from Tena-Sempere, 
Hum Reprod Update 2006)
The GPR54 receptor identified in the human is highly conserved among mammals with 
an 81% homology to the rat receptor. The receptor signals via phosphatidyl inositol 
biphosphate hydrolysis which results in accumulation of inositol triphosphates (IP3) 
and diacylglycerol (DAG), as well as, activation of extracellular regulated kinase 1/2 
(ERK1/2) and p38 kinase (Kotani et al., 2001).
Kisspeptin and its cognate receptor GPR54 are expressed mainly in the brain and 
placenta and they have been implicated in the initiation of puberty, regulation of adult 
fertility and in placentation. 
Mutations in the GPR 54 gene, as well as in the KiSS-1 gene are associated with 
isolated hypogonadotrophic hypogonadism in both humans and rodents (Seminara 
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et al., 2003, de Roux et al., 2003, Semple et al., 2005).   Hence kisspeptins and their 
native receptors seem to play a vital role in pubertal maturation as well as normal 
reproductive development (Funes et al., 2003, Seminara and Kaiser, 2005, Lanfranco 
et al., 2005, Tenenbaum-Rakover et al., 2007). In contrast a recent publication has 
demonstrated that pubertal development occurs in the absence of  kisspeptin/GPR 
54 signalling in mice with genetic ablation of the ligand and receptor  neurons (Mayer 
and Boehm, 2011). 
1.4.1.6 Kiss1 gene, kisspeptins and GPR-54 in pregnancy 
Horikoshi et al demonstrated elevation of plasma metastin in human pregnancy 
and localized its mRNA and protein expression to the syncitiotrophoblast layer of 
the placenta (Horikoshi, 2003). Kiss1 and its receptor GPR54 were identified among 
candidate genes to play an important role in the invasive and migratory properties of 
trophoblast cells (Janneau, 2002). 
By comparing mRNA signatures of first trimester placentae with those from the third 
trimester, one group demonstrated that Kiss1 and GPR-54  transcripts were abundant 
in the former, suggesting an important role in invasion (Bilban et al., 2004). They also 
showed that the smallest cleavage product (kisspeptin-10) inhibited trophoblast cell 
invasion. The expression of both ligand and receptor was demonstrated in villous 
trophoblast whereas only the receptor was expressed by extravillous trophoblast. 
They suggested an autocrine/paracrine control over invasion and furthermore 
demonstrated that this process was mediated via intracellular calcium mobilization. 
In the same study both Kiss-1and Kiss-1R mRNAs were highest in the first trimester 
in comparison to term, further suggesting a role of invasion inhibition for kisspeptin 
at a time when trophoblast invasion is at its highest. In contrast to tissue expression 
levels, circulatory kisspeptin concentrations increase with advancing gestation and 
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dramatically fall post-delivery (Horikoshi, 2003).  
Our understanding of trophoblast invasion is largely based on studies done on various 
villous and extravillous trophoblast cell lines, as well as rodent in-vivo and in-vitro 
experimental models (King et al., 2000). There are limited studies conducted on 
kisspeptins and placentation in humans. Recently, a group studied Kiss1 and MMP9 
expression in primary trophoblast cultures from 40 women with pre-eclampsia and 
compared them with those from 20 normal term pregnancies (Qiao et al., 2005b). 
Expression levels were measured using real-time PCR and Western blot analyses 
from the primary trophoblast cells. They analyzed the difference in Kiss1 and MMP9 
expression between normal and preeclamptic pregnancies and correlated their 
findings with perinatal outcome.  The expression of Kiss1 was significantly higher in the 
trophoblasts of preeclamptic women compared to normal pregnancy whereas that of 
MMP9 was significantly lower in preeclamptic than normal pregnancies. Furthermore 
there was significant positive correlation between MMP9 expression in preeclamptic 
women and neonatal birth weight. The opposite (significant negative correlation) was 
found for Kiss1 gene expression and neonatal birthweight. 
The same group found a positive correlation between invasive capacity and MMP9 
expression and a negative correlation for invasive capacity and Kiss1 expression by 
comparing mRNA expression from human placental tissue of molar, preeclamptic 
and normal pregnancies(Qiao et al., 2005a). Interestingly, a prospective study utilizing 
chorionic villous sampling of human first trimester placental tissue demonstrated no 
difference in MMP-2 or MMP-9 expression between pregnancies destined for health 
or preeclampsia (Huisman et al., 2004). One study (Yan et al., 2001) demonstrated 
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suppression of MMP-9 expression by Kiss1 via reduced NF-κβ binding to the MMP-9 
promoter while the other, using a gastric cancer cell-line showed that Kiss1 suppressed 
MMP-9 expression via  p38 MAP kinase signalling pathway (Lee and Kim, 2009)
Furthermore kisspeptin inhibits tumour angiogenesis by suppressing Sp1-mediated 
VEGF expression and FAK/Rho GTPase activation (Cho et al., 2009). In vitro, kisspeptin 
suppresses the sprouting of new vessels from placental arteries and tube-like structure 
formation in human umbilical vein endothelial cells (HUVECs) in a dose-dependent 
manner (Ramaesh et al., 2010). 
Kisspeptin therefore seems to be play some role in regulating the expression of 
genes involved in matrix degradation and angiogenesis both of which remain crucial 
pathways in placentation.
As discussed earlier there are permissive and inhibitory factors involved in trophoblast 
invasion on mutual sides of the maternal-fetal interface. Very few human studies have 
examined gene and protein expression on both sides of this interface, in a cohort of 
patients. In order to understand the molecular dynamics of maternal-fetal  dialogue, it is 
important to examine all components of this interface in both healthy and pathological 
pregnancies.
There is adequate evidence that kisspeptin and its cognate receptor, GPR54 play key 
roles in the control of trophoblast invasion and placental development. 
1.5 Transformation of  the Spiral Arteries  
Effective placentation is required for a successful pregnancy outcome. During 
placentation, transformation of the placental bed spiral arteries from high resistance 
low capacity vessels to low resistance high capacity ones is crucial to support the 
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developing fetus. The lack of transformation of these spiral arteries is associated 
with poor pregnancy outcomes such as preeclampsia and intrauterine growth 
restriction (IUGR) (Brosens, Robertson et al. 1967; Robertson, Brosens et al. 1967). 
Transformation of spiral arteries involves the replacement of vascular endothelial cells 
with endovascular trophoblast as well as vascular smooth muscle and elastin with 
trophoblast-embedded fibrinoid matrix. The result of loss of vascular smooth muscle 
and elastin is vessel independence from vasomotor activity and absent vascular recoil 
respectively. The effect of these changes are flaccid, dilated spiral arterial vessels with 
considerable volume citation.
The spiral arteries are branches of the basal arteries and have decidual and myometrial 
components. The initiation of spiral arterial transformation is thought to occur as early 
as the late luteal phase with progesterone-mediated changes to the basal decidua 
and junctional zone myometrium.  Some of these early decidualisation events include 
vacuolisation of the vascular endothelial and medial layers, vessel wall oedema likely 
driven by angiogenic factors like VEGF, disruption of the elastica and disorganization of 
the vascular smooth muscle. This is sometimes referred to as trophoblast-independent 
or decidua-associated remodeling and uNK cells likely play a crucial role in this phase 
prior to invasion of trophoblast cells.
The trophoblast dependent phase involves invasion of interstitial trophoblast stemming 
from cytotrophoblast columns of anchoring villi. These invading mononuclear 
interstitial trophoblast cells cluster around the decidual segments of spiral arteries 
as perivascular trophoblast and are thought to enter the already disrupted spiral 
arterial walls by intravasation. Having entered the vessel wall they likely emit apoptotic 
signals responsible for further vascular smooth muscle and elastin disruption and 
eradication, secrete fibrinoid material and replace vascular endothelial cells to 
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become endovascular trophoblast. Due to paucity of perivascular trophoblast around 
myometrial spiral arteries, endovascular trophoblast in these vessels is likely the 
result of intravascular migration of endovascular trophoblast from decidual spiral 
arteries rather than by intravasation of perivascular citation. It is more the scarcity of 
endovascular trophoblast in the myometrial rather than decidual spiral arteries that 
seems to be the initial insult in pregnancy-related disorders.
1.6 Failure of Transformation of  the Spiral Arteries : Clinical Sequelae 
1.6.1 Preeclampsia 
Preeclampsia is the leading cause of direct maternal deaths and contributes 
significantly to  perinatal  morbidity  and  mortality  in South  Africa and the rest of the 
world. This disorder is typified by new-onset proteinuria and hypertension after 20 
weeks of pregnancy which is part of a systemic multi-organ endothelial dysfunction 
in the mother and is often complicated by intrauterine growth restriction (IUGR) in the 
fetus. Despite extensive research focusing on this condition, the pathophysiology of 
preeclampsia still remains poorly understood however it is largely acknowledged that 
lack of deep spiral arterial transformation is at the core of its development. 
1.6.2 Intrauterine Growth Restriction 
Intrauterine growth restriction defines a clinical entity where the fetus fails to reach 
its maximum genetic growth potential. It has various causes including chromosomal 
abnormalities, congenital infections, inherited metabolic disorders and preeclampsia. 
It can however develop without any clinically apparent cause and is then known as 
isolated intrauterine growth restriction. The aetiology of the isolated form is likely related 
to poor placentation resulting in inadequate transformation of the spiral arteries.
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1.6.3 Aims of Study
The hypothesis of this study was that the expression of kisspeptin and/or its receptor 
as well as target gene regulation would be different across the maternal-fetal interface 
of normal and abnormal placentation.  
The aims of this study were therefore to
1. Investigate the expression of kisspeptin and its receptor GPR-54 in the maternal-
fetal tissues, namely the placenta, placental bed and decidua parietalis of healthy 
pregnancies.
2. Investigate the expression of kisspeptin-mediated genes, namely MMP-9 and 
angiogenic regulators (VEGF-A, PROK-1 and their receptors) in the maternal-fetal 
tissues of healthy pregnancies.
3. Explore differences in the maternal-fetal tissue expression of Kiss1, GPR-54 
and angiogenic ligands (VEGF-A and PROK-1) between healthy and preeclamptic 
pregnancies.
4. Investigate differences in maternal-fetal tissue expression and circulatory levels of 
kisspeptin, VEGF-A and PROK-1 in healthy and preeclamptic pregnancie.
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2.1 Tissue Sampling and Specimen Collection 
At caesarean section the placenta and placental bed were sampled using a technique 
previously employed by Pijnenborg and colleagues (Pijnenborg et al., 1991). In 
addition the decidua parietalis was sampled as a negative control, being a neutral 
site that has had no involvement in placentation. Each of the tissue samples collected 
was divided into in four parts and put into four different collection tubes. One tissue 
part was collected in RNA stabilisation solution (RNA Later®, Ambion Cat # AM 7021) 
and snap frozen in liquid nitrogen for RNA extraction. The second and third parts 
of the tissue samples were collected in empty screw–top Bijou tubes for protein 
extraction and kisspeptin stimulation studies. The fourth part of the sample was 
collected in paraformaldehyde in order to make wax-embedded tissue blocks for 
immunohistochemical studies.
2.2 Gene Expression Studies 
2.2.1 RNA Extraction 
One millilitre of TRIzol® reagent (InvitrogenTM Cat no 15596-018) was used per 50mg 
of tissue. The tissue was homogenised with a Tissue Ruptor® ((TR 12520437) Qiagen 
Instruments Hombrechikon, Switzerland) on dry ice to minimise RNA degradation and 
the homogenate was kept on ice for 10minutes. Then the homogenate mixture was 
centrifuged (12000rpm at 40C for 15min) to get rid of cellular debris. The supernatant 
was collected and added to 200ml of ice-cold BCP (1-Bromo-3-Chloro-Propane from 
Sigma Cat # B-96373) per 1ml of TRIzol utilised. The mixture was vigorously shaken 
for 15 seconds and incubated on ice for 10 minutes. The solution was centrifuged 
(12000rpm at 40C for 15min) to separate the protein from the RNA. The clear 
supernatant (RNA) was decanted into a new tube and 500ml of 100% propanol was 
added to precipitate the RNA. The tube was again centrifuged, propanol decanted 
27
Chapter 2 General Materials and Methods
and the sample air dried. Subsequently the RNA pellets were washed in 75% Ethanol 
and briefly air dried. The resultant pellets were resuspended in 10-100ml of DEPC 
(Diethylpyrocarbonate) water depending on the size of the pellet and the RNA solution 
was stored at -700C for cDNA synthesis. RNA concentration was determined by 
measuring  absorbance at 260nm and 280nm employing a NanoDrop® ND1000 UV-
Vis Spectrophotometer (NanoDrop Technologies).
2.2.2  Complementary DNA Synthesis 
Complementary DNA (cDNA) was synthesised from the RNA extracted from the tissue 
samples. The RNA was reverse transcribed with Multiscribe Reverse Transcription 
reagents from Applied Biosystems (Part number N808-0234). The reverse transcription 
reaction had a total volume of 20μl and consisted of DEPC H2O (3.7ml), 10x RT Buffer 
(2ml), MgCl2 (4.4ml), dNTPs (4ml), Random Hexamers(1ml), RNAse Inhibitor (0.4ml), 
Reverse Transcription Enzyme (0.5ml) and (2ml) of RNA. The thermal cycling parameters 
of the reaction were 250C for 10 minutes, 40C for 10 minutes, 480C for 45 minutes and 
950C for 5 minutes. This was carried out using the ABI GeneAmp® PCR System 2700 
(Applied Biosystems).
2.2.3   Real-Time Polymerase Chain Reaction 
Gene expression studies were conducted using the ABI 7900 Real-Time PCR machines 
from Applied Biosystems.  In addition Taqman PCR reagents, mastermix and 96-well 
plates from Applied Biosystems were utilized. 
For a single sample 50μl reaction (in duplicate) the following were added:  19.05μl 
H2O, 25μl PCR mastermix, 0.75μl 18s ribosomal RNA mix (forward primer, reverse 
primer and probe), 0.6μl each of target gene forward and reverse primers and 2μl 
each of target gene probe and cDNA sample. After mixing, each sample including 
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a no reverse transcriptase (negative control) and reference cDNA (positive control) 
were added to 96-well MicroAmp® PCR plates (Applied Biosystems, Warrington, 
UK) and sealed with nuclease-free MicroAmp® optical adhesion film. The standard 
thermal cycling protocol was conducted as follows: 500C for 2 min, 950C for 10 min 
and 40 cycles of 950C for 95 seconds and 600C for 1 min.  The following primer/probe 
pairs supplied by Sigma® pharmaceuticals were utilised (Table 2.1) in conjunction with 
the Taqman® mastermix (Applied Biosystems). 18s ribosomal RNA was used as an 
internal gene expression control. The ΔΔCt method was employed to analyse relative 
gene expression.
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Table 2.1   Primers and Probe Sequences used for Real-Time (RT) PCR Reactions
1GPR54 Forward Primer 5’-GGTGCTGGGCGACTTCAT-3’
GPR54 Reverse Primer 5’-CACACTCATGGCGGTCAGAGT-3’
GPR54 Probe
5’-[FAM]-TGCAAGTTCGTCAACTACATCCAGCAGG-[TAM-
RA]-3’
2Kiss1 Forward Primer 5’-GGCAAGCCTCAAGGCACTT-3’
Kiss1 Reverse Primer 5’-GGAAAAGCAGTAGCTGCCAAGA-3’
Kiss1 Probe
5’- [FAM]-TGCCTCTTCTCACCAAGATGAACTCACT-
GG-[TAMRA]-3’
3PROK1 Forward Primer 5’-GTG CCA CCC CGG CAG-3’
PROK1 Reverse Primer 5’-AGC AAG GAC AGG TGT GGT GC-3’ 
PROK1 Probe
5’-[FAM]-ACA AGG TCC CCT TCT TCA GGA AAC GCA-[TAM-
RA]-3’ 
4PROKR1 Forward Primer 5’-TCT TAC AAT GGC GGT AAG TCC A-3’
PROKR1 Reverse Primer 5’-CTC TTC GGT GGC AGG CAT-3’
PROKR1 Probe
5’-[FAM]-TGC AGA CCT GGA CCT CAA GAC AAT TGG-[TAM-
RA]-3’ 
5VEGF Forward Primer 5’-TAC CTC CAC CAT GCC AAG TG-3’
VEGF Reverse Primer 5’-TAG CTG CGC TGA TAG ACA TCC A-3’
VEGF Probe
5’-[FAM]-ACT TCG TGA TGA TTC TGC CCT CCTCCT 
T-[TAMRA]-3’
6MMP9 Forward Primer 5’-GGCCACTACTGTGCCTTTGAG-3’
MMP9 Reverse Primer 5’-GATGGCGTCGAAGATGTTCAC-3’
MMP9 Probe 5’-[FAM]-TTGCAGGCATCGTCCACCGG-[TAMRA]-3’
7VEGFR2 Forward Primer 5’-TTA CAG CTT CCA AGT GGC TAA GG-3’
VEGFR2 Reverse Primer 5’-ATT TTA ACC ACG TTC TTC TCC GAT AA-3’
VEGFR2 Probe
5’-[FAM]-CTT GGC ATC GCG AAA GTG TAT CCA CA-[TAM-
RA]-3’
8VEGFR1 Forward Primer 5’-ATG TGC CAA ATG GGT TTC ATG T-3’
VEGFR1 Reverse Primer 5’-ACT TGT TAA CTG TGC AAG ACA GTT TCA-3’
VEGFR1 Probe
5’-[FAM]-CTC TCC TTC CGT CGG CAT TTT TTC CAA-[TAM-
RA]-3’
918S Forward Primer 5’-CGG CTA CCA CAT CCA AGG AA-3’
18S Reverse Primer 5’-GCT GGA ATT ACC GCG GCT -3’
18S Probe 5’-[VIC]-TGC TGG CAC CAG ACT TGC CCTC -[TAMRA]-3’
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2.3   Protein Expression Studies 
2.3.1   Protein Extraction 
Tissue was lysed with cold RIPA lysis buffer containing (25mM Tris HCl pH 7.6, 150mM 
NaCl, 1% Triton X, 1% sodium deoxycholate and 0.1% SDS) that was supplemented 
with Urea to a final concentration of 4M and Complete® EDTA-free protease inhibitor 
tablets (ref 11 873 580 001) (Roche®). One millilitre of the supplemented RIPA was 
used per 50mg of tissue. The tissue was left in the buffer on ice for 30minutes. The 
mixture was poured into a mortar and snap-frozen with liquid nitrogen. The solid 
material was crushed into a fine powder using a pestle with intermittent use of liquid 
nitrogen as required. The powder was collected in 2ml epindorff tubes and centrifuged 
at 12000rpm for 15 minutes @ 40C. The supernatant was collected and the protein 
concentration quantified using the BCA (Bicinchoninic acid) method. 
2.3.2   Protein Quantification 
The Pierce BCA Protein Assay Kit (Prod # 23225) from Thermoscientific was used 
to quantify protein concentration according to the manufacturer’s instructions. Serial 
dilutions of bovine serum albumin (BSA) at 2mg/ml in 0.9% saline and 0.05% sodium 
azide were made for the standard curve. Ten microliters (10μl) of each standard solution 
and unknown samples were pipetted in triplicate onto a 96-well microplate. Using 
a multi-channel pipette, 200μl of working reagent 1:50 dilution of Reagent B (4% 
cupric sulphate): Reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic 
acid and sodium tartrate in 0.1M sodium hydroxide) was added to each sample well 
and the microplate incubated for 30 min at 370C. The samples were then placed in an 
ELISA microplate reader and absorbance read at 595nm. Protein concentrations were 
calculated from the BSA standard curve.
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2.3.3   SDS-PAGE and Western Blotting 
A total of 20mg of protein in 20ml was loaded per gel well on a stacking gel after 
denaturing in Laemmli buffer (125mM Tris HCL pH 6.8, 4% SDS, 20% glycerol, 5% 
2-mercapthoethanol and 0.05% bromophenol blue) at 950C for 5 minutes. The protein 
sample was separated on a 15 % SDS-PAGE resolving gel (Appendix). The gels were 
run at 110V for 80 minutes. Spectra® Multicolor Broad Range Protein Ladder (Product 
no 26634) from Thermoscientific was used to mark molecular weights of proteins in 
Kilodaltons (kDa).The gel was then blotted onto a 0.45mm PVDF membrane (Amersham 
Hybond-P).The protein transfer was done using a semi-dry technique (Novex® Semi-
dry Blotter (Cat No SD1000) Invitrogen) at a constant voltage of  14V for 90 min.  
The membranes were blocked on a shaker with 5% milk in TBST at room temperature 
for 1 hour. They were then incubated at 40C overnight with the primary antibody 
(Rabbit anti-VEGF A antibody (sc-152) Santa Cruz Biotechnology) at a dilution of 1:50 
in blocking solution. Two gels were simultaneously run for each sample resulting in 
two membranes, one for detection and the other for control. The twin membrane 
(negative control) was incubated with a pre-incubated mixture of anti-VEGF A and 
VEGF A blocking peptide.  For MMP9 protein detection rabbit anti-human MMP9 
antibody (Product no ab38898, abcam®) and MMP9 blocking peptide (Product no 
ab41067, abcam®) were used. The membranes were washed 3x with TBST for 5 min. 
and subsequently incubated with secondary antibody Goat Anti-Rabbit Peroxidase 
(GARP) at a dilution of 1: 5000 at room temperature for 1 hour and thereafter washed 
again with TBST for 5min. Visualisation was done by application of a peroxidase 
based chemiluminescent solution (Supersignal® West Pico Chemiluminescent 
Substrate –Thermoscientific (Prod no 34080) and development of the photographic 
film (Amersham Hyperfilm® ECL- GE Healthcare Limited (Product code 28906836)) in 
a dark room.
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2.3.4   Immunohistochemistry 
Wax-embedded tissue blocks were sectioned and fixed to slides (Histobond®) with 
the three sections of placenta, placental bed and decidua parietalis fixed across 
one slide. This arrangement ensured standardised treatment of sections across the 
maternal-fetal interface on one slide. In addition all slides were batch-stained in order 
to minimise “inter-slide” staining variability.
2.3.4.1   Kisspeptin Immunostaining 
The slides were de-waxed and rehydrated in xylene and decreasing concentrations 
of ethanol. Antigen retrieval was done by pressure cooking the slides in 0.01M Citrate 
Buffer. The slides were then blocked in 10% Hydrogen Peroxide in Methanol for 30 
mins in order to quench endogenous peroxide activity. Thereafter the slides were first 
washed in tap water and in Tris-Buffered Saline (TBS), (25mM Tris, 150mM NaCl, 2mM 
KCl, pH 7.4). A second blocking step was done with normal donkey serum (NDS) to 
reduce non-specific binding of the primary antibody. 
The slides were incubated at 40C overnight with the kisspeptin primary antibody 
(GQ2) diluted 1: 1500 in blocking serum (NDS). (The primary antibody was raised in 
the sheep against kisspeptin 54 and was obtained as a gift from Professor Bloom’s 
laboratory).The next morning the slides were washed in TBS (2 x 5mins) and secondary 
antibody Donkey Anti-Sheep Peroxidase (DAShP) IgG (Cat no 713-005-003, Jackson 
Immunoresearch) diluted 1: 750 in blocking serum was added. The slides were washed 
again in TBS (3 x 5mins). Then Tyramide Cyanine 5 Signal Amplification (Cat no NEL 
745, Perkin Elmer LAS, Inc) diluted (1:50) was applied to the slides and incubated at 
room temperature for 10minutes.The slides were then washed in TBS (2 x 5mins) and 
DAPI 405 used as a nuclear counterstain  at dilution of  1: 1000 in PBS was applied 
for 10mins at room temperature. The DAPI was washed off in TBS (2 x 5mins) and 
33
Chapter 2 General Materials and Methods
the slides mounted in Permaflour® mounting medium. Visualisation was done on the 
Zeiss LSM 710 META confocal laser microscope.
    
2.3.4.2   Kisspeptin Receptor (GPR-54) Immunostaining 
The slides were de-waxed, rehydrated and then blocked with 10% hydrogen peroxide 
(H2O2) in methanol. They were then washed in tap water and TBS and subsequently 
blocked with normal goat serum.  Incubation with primary antibody against GPR54 (R2 
1213 custom manufactured by EZ Biolabs raised in the rabbit) at a dilution of 1: 1600 
was done at 40C overnight. A similar  incubation with pre-immune rabbit serum at the 
same dilution was conducted as a negative control. The next morning the slides were 
washed in TBS and secondary antibody Goat Anti-Rabbit Peroxidase (1: 200) (Dako 
Cat no P0448) was applied.  The slides were again washed in TBS and Tyramide 546 
(Cyanine 3) Signal Amplification (Perkin Elmer LAS, Inc) was applied. The Tyramide 
was washed off in TBS and Sytox Green (1: 1000 in TBS) was used as a nuclear stain. 
After washing with TBS the slides were mounted in Permaflour®. The Zeiss LSM 710 
META confocal laser microscope was employed for visualisation.
2.3.4.3  MMP-9  Immunostaining 
The slides were de-waxed and rehydrated. Heat-mediated antigen retrieval in 0.01 
M citrate buffer was followed by quenching endogenous peroxide with 10% H2O2. 
Blocking to prevent non-specific antibody binding was done with NDS for 1 hour 
and primary rabbit anti-MMP9 antibody (ab38898 (1 mg/ml)) (1:200) from Abcam® 
was applied overnight. The slides were washed in TBS (3x 5min) and Donkey Anti-
Rabbit-555 (DAR-555) (1:1000) (A31572 from Invitrogen) was used as secondary 
antibody. The slides were again washed with TBS as before followed by staining 
with DAPI for nuclei. To visualize the slides, the Zeiss LSM 710 META confocal laser 
microscope was used.
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2.3.4.4  VEGF-A Immunostaining 
The slides were dewaxed rehydrated and antigen retrieved and blocked with 10% 
hydrogen peroxide in methanol. Normal Donkey Serum (NDS) was used for blocking 
to prevent non-specific binding. Rabbit Anti-VEGF A antibody (VEGF (A-20) (sc-152)-
Santa Cruz Biotechnology) at a dilution of 1:50 was applied overnight followed by three 
5 min TBS washes in the morning. Donkey Anti-Rabbit 555 (Invitrogen) at (1:1000) 
dilution was used as secondary antibody and thereafter washed (3x 5min) with TBS. 
DAPI (1: 1000) nuclear stain was subsequently applied followed by visualization on 
the confocal laser microscope as above.
2.3.4.5   VEGF-A and Pancytokeratin Co-immunostaining 
The slides were dewaxed, rehydrated, antigen retrieved and blocked with methanol 
hydrogen peroxide for half an hour. NDS was used as blocking serum and primary 
rabbit anti-VEGF A and mouse anti-human Pancytokeratin (AbID 0774/Cat no C2562, 
Sigma®) antibodies were mixed, applied to the slides and incubated overnight. The 
former was diluted at 1: 50 and the latter was used at a dilution of 1: 15 000. To wash 
off the primary antibodies, the slides were washed three times (5 mins ) with TBS and 
secondary antibodies DAR-555 (1:1000) and Goat Anti-Mouse 488 (GAM-488) (1:500) 
were simultaneously applied. Again three times TBS washes were done and then the 
nuclei were stained with DAPI. The Zeiss LSM 710 META confocal laser microscope 
was used for visualisation.
2.3.4.6   VEGF Receptor-1 (VEGF-R1) and VEGF Receptor-2 (VEGF-R2) 
Immunostaining 
The slides were de-waxed and rehydrated. Heat-mediated antigen retrieval was done 
in 0.01 M Citrate buffer followed by quenching of endogenous tissue peroxidase 
activity with 10% methanol hydrogen peroxide for 30 minutes. NDS was employed to 
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block non-specific antibody binding. The slides were incubated simultaneously with 
primary mouse anti-VEGFR1 (ab9540) and rabbit anti-VEGFR2 antibodies (ab2349) 
from Abcam® overnight. In the morning the slides were washed thrice with TBS for 
5 min and secondary GAM Alexa-488 and DAR-555 antibodies were applied for an 
hour. This was followed by TBS washes (3x 5min) and thereafter DAPI (1: 1000) was 
utilised for nuclei staining. The slides were visualised using the LSM 710 microscope.
2.3.4.7   EG-VEGF (Prokineticin-1) Immunostaining 
The slides were de-waxed, rehydrated and antigen retrieved in citrate buffer. 10% 
hydrogen peroxide in methanol was used to quench endogenous peroxide activity for 
30 min. After washing with distilled water and then TBS, the slides were blocked with 
NDS for 1 hour. Primary anti-PROK1 rabbit polyclonal antibody (ab42802, abcam®), 
diluted 1:50 in NDS was applied and incubated overnight at 40C. After washing with 
TBS three times (5mins each wash), secondary DAR-555 (A31572, Lot 819572- 
Invitrogen) antibody at a dilution of 1:1000 was applied on a shaker for 30minutes.
The slides were subsequently washed in TBS (3x 5mins) and DAPI (1:1000) was used 
as nuclear stain. The slides were visualised using the LSM 710 confocal microscope.
2.4   Enzyme-linked Immunosorbent Assays (ELISAs)
2.4.1   Maternal and Cord Serum Kisspeptin-10 Quantification 
The maternal and fetal circulatory kisspeptin-10 levels in the serum were measured 
using a human kisspeptin-10 sandwich enzyme immunoassay (EIA) kit from Phoenix 
Pharmaceuticals (EK-048-56). The assay detects human kisspeptin 10 (Tyr-Asn-Trp-
Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) from a minimum concentration of 0.06ng/ml to 
100ng/ml (Linear range 0.06-0.8ng/ml) with an inter- and intra-assay variability of 
<15% and <10% respectively. 
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Briefly, 50µl of kisspeptin standards and 50µl of patient samples were pipetted into a 96-
well immunoplate. To this, 25µl of primary kisspeptin antibody and 25µl of biotinylated 
kisspeptin peptide per well were added and incubated at room temperature for 2hours. 
The immunoplate was then washed 4 times with 350µl per well of 1X assay buffer. A 
100µl of Streptavidine-Horse Radish Peroxidase (SA-HRP) solution was added per 
well and incubated at room temperature for 1hour. 
The plate was again washed four times with assay buffer (350µl/well) and 100µl of 
tetramethyl-benzidine (TMB) substrate solution was added to each well and the plate 
incubated at room temperature for 1hour. The reaction was terminated with 100µl of 
2N HCl per well and absorbance read on a microplate reader at 450nm. A standard 
curve of relative absorbance versus concentration of standard solutions was plotted 
and the kisspeptin concentrations of the unknown samples were interpolated from the 
standard curve.
2.4.2   Maternal and Cord Serum VEGF-A Quantification  
The concentration of VEGF-A protein in the maternal and cord sera was analysed 
using a human VEGF-A Human ELISA kit from abcam® (ab 119566) with an  intra-
assay coefficient of variability (CV) of 6.2%. The microwells were washed with 400µl 
of wash buffer (PBS with 1% Tween 20) and thereafter 100 µl of VEGF-A protein 
standards and serum samples were added to a pre-coated 96-well plate. The plate 
was covered with an adhesive film and incubated at room temperature on a shaker for 
2hours to allow binding to pre-coated antibody. The plate was then washed six times 
with wash buffer followed by addition of a 100 µl of biotinylated anti-human VEGF-A 
antibody into each well and incubation of the plate at 37ºC on a shaker for 1 hour. 
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The plate was again washed six times and 100µl of Streptavidin-HRP was added 
to each well followed by incubation of the plate on a shaker for 30 minutes at room 
temperature. The plate was then washed again six times with wash buffer and a 100µl 
of TMB colour developing agent was added to each well and incubated at room 
temperature in the dark for 10 minutes. 
Colour development was monitored until the highest VEGF-A standard had developed 
a dark blue colour at which point a 100µl of Stop Solution (1M Phophoric acid) was 
added into each well and the absorbance immediately read at 450nm on a microplate 
reader. A standard curve of relative absorbance versus concentration of standard 
solutions was plotted and the concentration of VEGF-A in the samples was interpolated 
from the standard curve. 
2.4.3   Maternal and Cord Serum EG-VEGF Quantification
The concentration of EG-VEGF (Prokineticin-1) protein in the maternal and cord sera 
was analysed using a human EG-VEGF ELISA kit from abcam® (ab 119591). Briefly, 
100µl of EG-VEGF protein standards and serum samples were added to a pre-coated 
96-well plate. The plate was incubated at 37ºC for 90 minutes to allow binding to pre-
coated antibody. A 100 µl of biotinylated anti-human EG-VEGF antibody was added 
into each well and the plate was incubated at 37ºC for 60 minutes. The plate was then 
washed three times with 0.01M TBS and a 100 µl of Avitin-Biotin-Peroxidase Complex 
(ABC) at a dilution of 1:100 was added into each well and the plate incubated at 37ºC 
for 30 minutes. 
The  plate  was then washed five times with TBS and 90 µl of 3,3’,5,5’- 
tetramethylbenzidine (TMB) colour developing agent was added to each well and the 
plate was incubated in the dark for 30 minutes at 37ºC. Finally, a 100 µl of TMB 
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stop solution was added into each well and the O.D. absorbance immediately read 
at 450nm on a microplate reader. A standard curve of relative absorbance versus 
concentration of standard solutions was plotted and the EG-VEGF concentrations of 
the samples were calculated from the standard curve. 
2.5   Statistical Analysis        
One Way Analysis Of Variance (One Way ANOVA)  followed by Dunn’s Multiple 
Comparison’s Test was utilized to compare gene expression in different maternal-fetal 
tissues. The Mann-Whitney test was employed to compare tissue mRNA transcript 
expression as well as differences in circulating protein levels between healthy and 
preeclamptic pregnancies. The statistical package utilized was GraphPad Prism 
version 5.00 for Windows, GraphPad Software, San Diego California USA, www.
graphpad.com. Statistical significance was set at P < 0.05 with (***), (**) and (*) 
signifying p<0.0001, p<0.001 and p<0.05 respectively.             
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3.1  Abstract 
Genes involved in invasion of trophoblast cells and angiogenesis are crucial in 
determining pregnancy outcome. The expression profiles of candidate genes was 
examined  in both fetal and maternal tissues to enhance our understanding of maternal-
fetal  dialogue. The expression of genes involved in trophoblast invasion, namely Kiss1, 
Kiss1 Receptor (GPR-54) and MMP9 as well as the expression of angiogenic ligands 
Vascular Endothelial Growth Factor-A (VEGF-A) and Prokineticin-1 (PROK1) was 
investigated and their respective receptors (VEGFR1, VEGFR2 and PROK1R) across 
the maternal-fetal  interface of healthy human pregnancies. The placenta, placental 
bed and decidua parietalis were sampled at elective caesarean delivery. Real-time 
PCR (RT-PCR) was used to investigate transcription, while immunohistochemistry 
and Western blot analyses were utilized to study protein expression. 
The expression of Kiss1 (p<0.001), GPR-54 (p<0.05) and MMP9 (p<0.01) were higher 
in the placenta compared to the placental bed and decidua parietalis. In contrast, 
the expression of VEGF-A was highest in the placental bed (p<0.001). VEGF receptor 
mRNA expression studies revealed differential expression of VEGFR1 and VEGFR2 
with VEGFR1 expression highest in the placenta (p<0.01) and VEGFR2 was most 
expressed in the placental bed (p<0.001). Lastly, both PROK1 (p<0.001) and its 
receptor PROK1R (p<0.001) had highest expression in the placenta. 
The findings that genes associated with trophoblast invasion were highly expressed in 
the placenta suggest that the influence on invasion capacity may largely be exercised 
at the fetal level. Whereas the findings on angiogenic gene expression profiles suggest 
that angiogenesis may be regulated by two distinct pathways with the PROK1/
PROK1R system specifically mediating angiogenesis in the fetus and VEGFA/VEGFR2 
ligand-receptor pair predominantly mediating maternal angiogenesis. 
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3.2  Introduction 
Effective placentation is required for successful pregnancy outcome. During 
placentation, transformation of the spiral arteries from high resistance low capacity 
vessels to low resistance high capacity structures is crucial for successful support 
of the conceptus. The lack of transformation of these spiral arteries is associated 
with poor pregnancy outcomes such as preeclampsia and intrauterine growth 
restriction (IUGR) (Brosens et al., 1967, Robertson et al., 1967). The transformation 
of spiral arteries is determined by adequate endovascular invasion of extravillous 
trophoblast (EVT) cells. The ability of EVT cells to express gelatinases like MMP9 
aids extracellular matrix degradation and enhances invasiveness. The expression of 
MMP9 in particular, has been associated with high invasiveness, while that of Tissue 
Inhibitors of Metalloproteases (TIMPs) markedly reduces this invasive potential (Xu et 
al., 2000, Luo et al., 2011). Kiss1 gene was initially discovered as a tumour metastasis 
suppressor gene of melanoma cells but this has subsequently been demonstrated in 
various cancer cell-lines, animal models and human cancer tissue (Lee and Welch, 
1997, Li et al., 2009, Liang and Yang, 2007). The Kiss1 gene encodes peptides known 
appropriately as kisspeptins (kp) and posttranslational processing of the original Kiss1 
transcript results in kisspeptins of various lengths (kp-54,-14,-13 and -10) of which 
the smallest cleavage product, kp-10, has particular relevance to the placenta (Bilban 
et al., 2004). Kisspeptins mediate their functions via  G-Protein Coupled Receptor 54 
(GPR54) also known as Kiss1 Receptor (Kiss-1R) (Ohtaki et al., 2001, Muir et al., 2001, 
Kotani et al., 2001). 
The molecular machinery and pathways involved in tumour metastasis and invasion 
of extravillous trophoblast (EVT) cells into the maternal decidua are similar (Ferretti et 
al., 2007). However the invasiveness of trophoblast cells is highly regulated temporally 
and spatially. The highest invasion is observed in the first trimester of pregnancy 
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and geographically only extends as deep as the inner third of the myometrium. The 
clinical repercussions of ‘‘overinvasion’’ and ‘‘underinvasion’’ are placenta accreta as 
well as preeclampsia and IUGR, respectively. The former leads to massive obstetric 
haemorrhage secondary to retained placenta at the time of delivery while the latter 
(a consequence of maternal vascular maladaptation), contributes significantly to 
maternal and perinatal mortality, particularly in the developing world  (Moodley, 2011). 
Kisspeptins limit the invasion of primary trophoblast cells and EVT cell-lines in vitro 
(Bilban et al., 2004). Furthermore up-regulation of Kiss1 expression and down-regulation 
of MMP9 gene expression have been associated with pregnancies complicated by 
preeclampsia and IUGR (Qiao et al., 2005b, Qiao et al., 2005a). Interplay between 
diverse factors affecting EVT invasion comprises a delicate equilibrium between pro-
invasive and anti-invasive factors which is required for adequate invasion and a healthy 
gestation. Genes involved in angiogenic pathways appear to play a central role in 
achieving this equilibrium because ultimately the final common pathway to trophoblast 
invasion is spiral arteriolar transformation. In addition it has been demonstrated that the 
transformation of EVT cells from expressing an epithelial-type cell adhesion profile to 
an endothelial-type one enhances their invasiveness and subsequent transformation 
of spiral arteries (Zhou et al., 1997). 
Angiogenesis, the development of new vessels from existing vessels plays an 
important role in placentation (Reynolds et al., 2001, Kaufmann et al., 2004). This 
process is driven by a host of angiogenic factors and their respective receptors 
and under physiological conditions only occurs during ovarian folliculogenesis, 
embryogenesis and placentation (Carmeliet, 2005). Among other angiogenic factors 
during embryogenesis and placentation, Vascular Endothelial Growth Factor A 
(VEGF-A) is key. The endometrial mRNA transcript of VEGF-A increases in the luteal 
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phase in preparation for implantation (Demir et al., 2007). Furthermore VEGF-A ligand 
and receptor knockouts result in embryonic demise, underpinning the importance of 
this angiogenic factor in the early stages of human placentation and development 
(Carmeliet et al., 1996). The expression of VEGF-A in the placenta has been extensively 
studied (Sharkey et al., 1993, Charnock-Jones et al., 1994, Clark et al., 1996, Clark et 
al., 1998b).
More recently endocrine gland specific VEGF (EG-VEGF), also known as Prokineticin-1 
(PROK1) has been described (Le Couter et al., 2001). EG-VEGF, similar to VEGF, 
induces proliferation, migration and fenestration in capillary endothelial cells but is only 
expressed in steroidogenic organs such as the ovary and the placenta (Maldonado-
Perez et al., 2007). The role of EG-VEGF is thought to be complementary to that of 
VEGF in these tissues.
The majority of factors involved in trophoblast invasion have mainly been studied 
in the fetal compartment of the maternal-fetal  interface  i.e. the placenta. Very few 
studies have examined both sides of this interface concomitantly. To understand 
the molecular and cellular interactions involved in maternal-fetal dialogue, both 
components of this interface should be studied in healthy pregnancies before exploring 
pathological pregnancies. Furthermore, the expression of invasion-limiting Kiss1 and 
that of angiogenic factor EG-VEGF have never been investigated across the maternal-
fetal interface of pregnancy. In addition the expression of key angiogenic factor VEGF 
and its complementary associate EG-VEGF have never been compared across this 
interface. 
Hence the aim of this study was to investigate the expression of genes involved 
in trophoblast invasion, (Kiss-1 and MMP-9) along with that of angiogenic ligands 
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(VEGF-A, PROK1) and their respective receptors (VEGFR1, VEGFR2 and PROK1R) 
across healthy maternal-fetal tissues, namely the placenta, placental bed and decidua 
parietalis.
3.3     Materials and Methods 
3.3.1   Ethics Statement
The study was approved by the Human Research Ethics Committee of the Faculty of 
Health Sciences, University of Cape Town (REF: 080/2008). Written informed consent 
was obtained from all patients and the research was conducted according to the 
ethical principles of the Helsinki Declaration  (2001). Patients were counselled in their 
language of choice prior to the day of their elective procedure. They were presented 
with Patient Information Leaflets which provided the details of the study. The capacity 
of the patients to comprehend this information was always assessed and where 
there was doubt about comprehension, consent for study participation was withheld. 
Patients decision to participate in the study did not compromise their management 
and care. The patients were at liberty to make this choice without coercion. The 
clinicians responsible for the patient’s care were not involved in the recruitment for 
these studies.
3.3.2   Study Participants
All recruited patients had elective caesarean delivery in the absence of labour. The 
inclusion criteria for the study were healthy patients with singleton pregnancies 
undergoing elective caesarean section for the indication of previous caesarean 
section or fetal malpresentation. Patients in labour, with a background of two previous 
caesarean sections, multiple pregnancies, with pregnancy-related complications such 
as gestational diabetes, gestational hypertention, placenta praevia, preeclampsia, 
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intrauterine growth restriction as well as patients with underlying medical disorders 
were excluded from the study. Patients were recruited from Groote Schuur and 
Mowbray Maternity Hospitals in Cape Town, South Africa.
3.3.3   Tissue Sampling and Specimen Collection
The placenta and placental bed were sampled at elective caesarean section using a 
previously described technique (Pijnenborg et al., 1991). Briefly, prior to delivery of 
the placenta, apposing sections of the placenta and placental bed were marked by 
placing a needle and suture from the placenta and traversing the uterine wall. A core 
of the placental tissue around the suture in apposition to the maternal surface (i.e 
which contains the maternal end of the placenta) was then sampled and the rest of 
the placenta delivered. The section of the placental bed where the sampled placenta 
was resident could then be identified with the aid of the remaining suture and was 
subsequently biopsied. The adequacy of the sampled placental bed was confirmed 
by an independent histopathologist.  In addition, the decidua parietalis which has no 
involvement in placentation was sampled. Collected tissue samples were divided into 
three portions. One portion was collected for RNA extraction, while the second and 
third portions were utilised for protein extraction and preparation of wax-embedded 
tissue blocks respectively.
3.3.4   RNA Extraction
1 ml of Trizol reagent (Invitrogen®) was used per 50 mg of tissue. Tissue was 
homogenised on ice with a Tissue Ruptor® (Qiagen). The homogenate was centrifuged 
using the Eppindorff 5804 R machine (15294 g at 4 degrees celcius for 15 minutes 
(mins)) and the supernatant was collected and added to 200 ml of ice-cold BCP 
(1-Bromo-3-Chloro-Propane (Sigma). The mixture was shaken for 15 seconds (secs) 
and kept on ice for 10 mins. The solution was centrifuged again and 500 ml of propanol 
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was added to precipitate the RNA. The RNA pellets were washed in 75% ethanol, air 
dried and re-suspended in DEPC-treated water.
3.3.5   cDNA Synthesis
RNA was reverse transcribed with Multiscribe Reverse Transcription reagents 
(Applied Biosystems). For a 20 ml reverse transcription reaction, the following were 
used; DEPC-treated H2O (3.7 ml), 10x RT Buffer (2 ml), MgCl2 (4.4 ml), dNTPs (4 
ml), Random Hexamers (1 ml), RNAse Inhibitor (0.4 ml), Reverse Transcriptase (0.5 
ml) and (2 ml) of RNA. The ABI GeneAmp® 2700 Thermal Cycler was used and the 
cycling parameters were 25° C (10 mins), 4° C (10 mins), 48° C (45 mins) and 95° C (5 
mins). Real-Time PCR Gene expression studies were conducted using the ABI 7900 
RT-PCR instrument (Applied Biosystems). The standard thermal cycling protocol was 
conducted as follows: 50° C for 2 mins, 95° C for 10 mins and 40 cycles of (95° C for 
95 secs and 60° C for 1 min). 
The Genebank accession numbers of the genes investigated are as follows: KiSS1 
(NM_002256), GPR-54  (NM_032551), MMP9 (NM_004994), VEGFA (NM_001171623), 
VEGFR1 (FLT) (NM_002019), VEGFR2 (KDR) (NM_002253), PROK1 (NM_032414), 
PROKR1 (NM_138964). Primer/Probe pairs corresponding to these genes (Sigma 
Pharmaceuticals) were utilised (Table 1) in conjunction with the Taqman® Mastermix. 
All RT-PCR gene expression data is presented as Means ± SEM and gene expression 
was relative to 18s ribosomal RNA (internal control) and reference cDNA. 
3.3.6  Immunohistochemistry 
Tissue blocks were sectioned and fixed to slides (Histobond®) with the placenta, 
placental bed and decidua parietalis fixed across one slide and stained together. 
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3.3.6.1   Kisspeptin immunostaining.
Slides were de-waxed in xylene and rehydrated in decreasing concentrations of 
ethanol. Antigen retrieval was done by pressure cooking the slides in 0.01 M Citrate 
Buffer. The slides were then blocked in 10% Methanol Hydrogen Peroxide for 30 
mins, washed in water and then TBS (Tris-Buffered Saline). Normal Donkey Serum 
(NDS) was used for blocking followed by incubation with Sheep anti-kisspeptin-54 
(GQ2) antibody (1:1500) (provided by Professor Bloom’s laboratory) overnight at 
4° C. Thereafter slides were washed in TBS (3x5 mins) and incubated for 30 mins 
with secondary Donkey anti-Sheep Peroxidase antibody (Jackson Immunoresearch) 
(1:750) (1.8 mg/ml). The slides were washed again in TBS (365 mins) and incubated for 
10 mins with Tyramide Cyanine-5 (Perkin Elmer) (1:50). Thereafter slides were washed 
in TBS (2x5 mins) and microwaved in citrate buffer for 2.5 mins and incubated in hot 
buffer for 30 mins. They were then washed in TBS and incubated with Mouse anti-
α-Smooth Muscle Actin antibody (Sigma Aldrich) (1:5000) for 1 hour. After washing 
in TBS, secondary Donkey anti-Mouse-555 (DAM-555) (1:200) (2 mg/ml) (Invitrogen) 
antibody was applied for 30 mins and washed off with TBS. Nuclear stain DAPI 405, 
(1:1000 in PBS), was applied for 10 mins at room temperature and washed in TBS. 
Slides were then mounted with Permaflour® and viewed with Zeiss LSM 710 META 
confocal microscope.
3.3.6.2 GPR54 immunostaining. 
The same protocol as above was followed except no antigen retrieval was required 
and Normal Goat Serum was used for blocking. Primary Rabbit anti-GPR54 (R2 
1213) custom manufactured by EZ Biolabs (1:1600) was used. Pre-immune serum 
was utilised as negative control. Goat anti-Rabbit Peroxidase (1:200) (Dako) was used 
as secondary antibody followed by Tyramide-546 (Cyanine-3) (Perkin Elmer). Sytox 
Green (1:1000 in TBS) was used to stain the nuclei.
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3.3.6.3 MMP9 immunostaining. 
The slides were de-waxed and rehydrated. Heat-mediated antigen retrieval in 0.01 M 
citrate buffer was followed by quenching endogenous peroxide with 30% hydrogen 
peroxide in methanol. Blocking to prevent non-specific antibody binding was done 
with NDS and primary rabbit anti-MMP9 antibody (ab38898 (1 mg/ml)) (1:200) from 
Abcam® was applied overnight. Donkey Anti-Rabbit-555 (1:1000) (A31572 from 
Invitrogen) was used as secondary antibody followed by DAPI staining for nuclei. 
PROK1 immunostaining. 
3.3.6.4 PROK1 immunostaining.
The slides were prepared as above with antigen retrieval, blocked with NDS and 
incubated with primary Rabbit anti-PROK1 antibody (Abcam®) (1:50) in NDS. Donkey 
Anti-Rabbit-555 (DAR-555) (1:1000) (2 mg/ml) from Invitrogen was used as secondary 
antibody and the nuclei were stained with DAPI (1:1000 in PBS). 
3.3.6.5 VEGF-A immunostaining. 
Slides were de-waxed, rehydrated, antigen retrieved and bathed in hydrogen peroxide 
for 30 mins. Blocking was done with NDS. Rabbit Anti-VEGF A antibody (VEGF (sc-
152) (1:50) (200 mg/ml) (Santa Cruz) and DAR-555 (1:1000) were used as primary and 
secondary antibody respectively. The nuclei were stained with DAPI. 
3.3.6.6 VEGF-A and Pancytokeratin Co-Immunostaining. 
Slides were de-waxed, rehydrated, antigen retrieved and blocked with hydrogen 
peroxide in methanol. NDS was used for blocking. Rabbit anti-VEGF-A (1:50) and 
Mouse anti-Pancytokeratin (1:15000) (Sigma) were applied to the slides and incubated 
overnight. DAR-555 (1:1000) and Goat Anti-Mouse Alexa-488 (1:500) in NDS were 
used as secondary antibodies. DAPI was used to stain the nuclei. 
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3.3.6.7 VEGFR1 and VEGFR2 Co-Immunostaining. 
The slides were de-waxed and rehydrated. Heat-mediated antigen retrieval was done in 
0.01 M Citrate buffer followed by quenching of endogenous tissue peroxidase activity 
with 30% methanol hydrogen peroxide for 30 minutes. NDS was employed to block 
non-specific antibody binding. The slides were incubated simultaneously with mouse 
anti-VEGFR1 (ab9540) and rabbit anti-VEGFR2 antibody (ab2349) from Abcam®. 
Goat Anti-Mouse Alexa-488 and Donkey Anti-Rabbit-555 were used concurrently as 
secondary antibodies. DAPI was utilised for nuclei staining. 
3.3.7 Protein Extraction and Quantification 
RIPA lysis buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl, 1% Triton X, 1% sodium 
deoxycholate and 0.1% SDS) was used for tissue lysis. 4M Urea and protease inhibitor 
tablets (Roche®) were added to the buffer. The tissue was incubated on ice for 30 
mins, then poured into a mortar, snap-frozen with liquid nitrogen and crushed into 
fine powder using a pestle. The powder was collected in 2 ml epindorff tubes and 
centrifuged at 12000 rpm for 15 mins @ 4°C. The supernatant was collected and protein 
concentration quantified using the Pierce BCA Protein Assay Kit (Thermoscientific). 
3.3.8 Western Blot Analysis 
20 mg of protein/well was loaded after denaturing in loading buffer at 95°C for 5 
mins. The proteins were separated on a 15% SDS-PAGE gel run at 110 V for 80 mins. 
The gel was then blotted onto a 0.45 mm PVDF membrane (Amersham Hybond-P) 
using Novex® Semi-dry Blotter (Invitrogen). The membranes were blocked at room 
temperature for 1hour in 3% BSA and then incubated at 4°C overnight with Rabbit 
anti-VEGF-A antibody (sc-152) (1:50). For negative control the membrane was pre-
incubated with a mixture of anti-VEGF-A and VEGF-A blocking peptide (Abcam®). 
After washing, Goat anti-Rabbit Peroxidase (1:5000) was applied and the blot was 
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visualised using a film (Amersham HyperfilmTM ECL- GE Healthcare Limited). Beta-
Actin (β-Actin) was used as loading control.
3.3.9 Statistical Analysis
Graphpad 5 Prism software (version 5.00 for Windows, GraphPad Software, San 
Diego California USA, www.graphpad.com) was utilised for statistical analysis with 
One-Way ANOVA followed by Dunn’s Multiple Comparison’s Test. P<0.05 conferred 
statistical significance.
3.4 Results
3.4.1 Clinical Data 
Twenty-eight patients with healthy pregnancies were included in the study. The 
indications for caesarean section were a previous caesarean section in 23 patients 
(82.14%) and malpresentations in five (17.86%) patients. The clinical parameters are 
presented as means with standard error of the means (Mean ± SEM) (Table 3.1).
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Table 3.1 Patient Data
  
    Age (years)    Gravidity      Parity Gestation (weeks)
       Mean ± SEM 28.47 ± 0.87 2.433 ±  0.18           1.1 ±  0.16             38.03 ± 0.06 
Table depicting patients clinical data  presented as means with standard error of the 
means (SEM) showing  Age ( in years), Gravidity (number of pregnancies irrespective 
of viability) Parity (number of pregnancies that have reached viability) and Gestation 
(duration of pregnancy in weeks)
3.4.2 Kiss1 and GPR54 Expression are Highest in the Placenta
The expression of Kiss1 and GPR54 genes in the placenta, placental bed and decidua 
parietalis was determined by RT-PCR (Fig. 3.1A). There was seven times more Kiss1 
gene expressed in the placenta compared to the placental bed and eighteen times 
more Kiss1 gene expression in the placenta compared to the decidua parietalis 
(p<0.001). However there was no significant difference in Kiss1 gene expression 
between the placental bed and the decidua parietalis. The gene expression level of 
GPR-54 was only modestly higher (1.6 times) in the placenta compared the placental 
bed and decidua parietalis (Fig. 3.1B) and its expression in the placenta was much 
lower compared to that of Kiss1.
Immunohistochemical studies detected kisspeptin protein expression only in the 
syncytiotrophoblast layer of the placenta (Fig. 3.1C). GPR-54 protein was expressed 
in the placenta and specifically localized to the villous cytotrophoblast as well as 
extravillous trophoblast cell populations (Fig. 3.2A-C). No GPR54 immunostaining 
was observed in the decidua basalis and parietalis.
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Figure 3.1  Kiss1 and GPR54 (Kiss1 R) expression in the Placenta, Placental bed 
and Decidua parietalis. Real-time PCR (Means ± SEM) showing Kiss1 (A) and GPR54 
(B) expression in the three maternal-fetal  tissues. (***) and (*) signify p<0.001 and 
P<0.05 respectively. (C) shows kisspeptin immunostaining in the Placenta, Placental 
Bed and Decidua Parietalis, with kisspeptin protein expression (green fluorescent 
staining) in the placental syncitiotrophoblast (sTB) layer. Smooth Muscle Actin (yellow) 
was used as a positive control for slide staining and can be seen staining vascular 
smooth muscle (vsm) and smooth muscle (sm). The decidua basalis (db) and decidua 
parietalis (dp) can be seen in the placental bed and decidual sections respectively. 
Kisspeptin staining is negative in the placental bed and decidua parietalis. The nuclei 
were stained with Dapi (blue)
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A (anti-GPR54) B (anti-GPR54) C (pre-immune) 
Figure 3.2  GPR54 (Kiss1R) immunostaining in the Placenta. 
Fig 3.2 demonstrates GPR54 immunohistochemistry with individual villous 
cytotrophoblast cell staining for GPR54 (red) in the placental villus (pv) (A). (B) shows 
GPR54 (red) immunostaining of villous cytotrophoblasts (vCT), cytotrophoblast 
columns (CC) and extravillous trophoblast cells (EVTs). The placenta is stained with 
GPR54 pre-immune serum (negative control) in (C). The nuclei are stained with Sytox 
Green (green) in all images.
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3.4.3   MMP9 Transcript Expression is Highest in the Placenta
Next the expression of MMP9 mRNA in the three maternal-fetal  tissues was determined. 
The expression of MMP9 mRNA was at least two-fold higher in the placenta compared 
to the placental bed and four-fold higher in the placenta compared to the decidua 
parietalis (Figure 3.3A). There was no difference in MMP-9 mRNA expression between 
the placental bed and decidua parietalis. Immunohistochemistry was used to localize 
MMP9 protein in the placenta, placental bed and decidua parietalis (Figure 3.3B). 
MMP9 protein was localized in the villous trophoblast cells and mesenchyme of the 
placenta while in the placental bed the epithelial border of the decidua basalis stained 
positive for MMP9. There was minimal MMP9 staining in the decidua parietalis. 
3.4.4   VEGF-A Gene and Protein Expression are Highest in the  
           Placental Bed
The expression of major angiogenic factor VEGF-A gene and protein were investigated 
in the placenta, placental bed and decidua parietalis. VEGF-A gene expression was 
7-fold higher in the placental bed compared to the placenta (p<0.001) and 1.6-fold 
higher in the placental bed compared to the decidua parietalis (Figure 3.4A). After 
protein extraction and quantification from the three maternal-fetal tissues, Western 
Blot analysis confirmed RT-PCR findings showing more VEGF-A protein expressed 
in the placental bed and decidua parietalis compared to the placenta (Figure 
3.4B). Immunostaining of placental sections showed mild VEGF-A staining of the 
syncytiotrophoblast, cytotrophoblast as well as staining of villous capillary endothelial 
cells (Figure 3.4C). On the other hand, strong VEGF-A immunostaining was observed 
in the placental bed sections relative to the placenta and decidua parietalis. Immuno-
co-localization of VEGF-A and Pancytokeratin (a marker for trophoblast cells) revealed 
that placental bed VEGF-A expression was predominantly from extravillous trophoblast 
cells and trophoblast giant cells (Figure 3.4D). 
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Figure 3.3  MMP9 expression in the Placenta, Placental Bed and Decidua Parietalis. 
(A) shows relative MMP9 mRNA expression based on RT-PCR in the Placenta, Placental 
Bed and Decidua Parietalis. (***) and (**) signify p<0.001 and p<0.01 respectively. (B) 
depicts localization of MMP-9 protein at the three maternal-fetal sites. In the placenta 
MMP9 immunostaining (red) was observed in the villous mesenchyme (vM) as well as 
the villous trophoblast cells (vT) of the placental villus (pv). In the placental bed MMP9 
staining was mainly located on the decidual border of the decidua basalis (Db). In 
comparison, there was minimal MMP9 staining in the border of the decidua parietalis (Dp). 
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Figure 3.4  The expression of VEGF-A in the Placenta, Placental Bed and 
Decidua Parietalis. Real-time PCR (Means ± SEM) showing mRNA expression of 
VEGF-A, in the three maternal-fetal tissues (A). (***) and (**) signify p<0.001 and p<0.01 
respectively. (B) illustrates VEGF-A Western Blot Analysis of the Placenta, Placental 
Bed and Decidua Parietalis obtained from diff erent patients. Bands are present in 
both the maternal Placental Bed (PB) and Decidua Parietalis (DP). Bands between 20 
and 40 Kd represent the various VEGF-A isoforms. The molecular weight of VEGF is 
20 Kd (Kilodaltons) while that of the homodimer is 40 Kd. (C) demonstrates VEGF-A 
immunostaining in the placenta with VEGF-A protein (red) expressed in both the 
syncytiotrophoblast (sTB) and cytotrophoblast (cTB) cells  of the placental villus (pv). 
VEGF-A staining is also observed in the endothelial cells of villous capillary vessels 
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(vCv). DAPI (blue) is used to stain the nuclei. (D) shows co-localisation of VEGF-A (red) 
and Pancytokeratin (PCK) (green) in a cluster of Extravillous Trophoblast (EVT) cells 
staining yellowish-orange. Multinucleated Trophoblast Giant Cells (TGCs) can be seen 
amongst the EVTs. The lumen of a spiral artery (SA) containing red blood cells can be 
noticed on the left. DAPI (blue) was used to stain nuclei. The nuclei of the TGCs are 
different in morphology and size in comparison to those of the surrounding cells. 
3.4.5   VEGFR1 and VEGFR2 Transcripts and Protein are Differentially 
Expressed Across the Maternal-fetal  Interface
VEGF-A mediates its effects via interaction with a number of its receptors. The mRNA 
and protein  expression of angiogenic receptors, VEGF Receptor 1 (VEGFR1) and 
VEGF Receptor 2 (VEGFR2) was examined in the three maternal-fetal tissues. Using 
RT-PCR, VEGFR1 also known as FLT (fms-like tyrosine kinase) transcript expression 
was highest in the placenta (3-fold higher expression in the placenta compared to the 
placental bed and 7-fold higher expression in the placenta compared to the decidua 
parietalis) (Figure 3.5A). In contrast, the mRNA expression of VEGFR2 also known as 
Kinase Domain Receptor (KDR) was highest in the placental bed (almost 4-fold more 
compared to the placenta) (Figure 3.5B). 
Using immunohistochemical co-localisation of VEGFR1 and VEGFR2, it was found 
that in the placental sections, VEGFR1 protein  was expressed by the cytotrophoblast 
columns (CC) and extravillous cytotrophoblast (EVT) while in the placental bed it 
was expressed by interstitial trophoblast (Figure 3.5C). On the other hand, VEGFR2 
protein was mostly immunolocalised to the placental bed with minimal expression 
in the placenta. VEGFR2 staining in the placental bed was neither from interstitial 
trophoblast nor decidual macrophages as verified with CD68 staining but was limited 
to the decidual stroma.
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3.4.6   PROK1 Transcript and Protein and PROK1R Transcript 
Expression are Highest in the Placenta 
The mRNA expression of both Prokineticin 1 (PROK1) and its receptor PROK1R were 
highest in the placenta compared to the placental bed and decidua parietalis (Figure 
3.6A and 3.6B). Immunohistochemical staining of the placental sections localized 
PROK1 protein to the microvillous border of the placental syncytiotrophoblast layer 
(Fig 3.6C) with minimal PROK1 immunostaining of extravillous trophoblast cells (EVTs) 
in placental bed sections. 
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Figure 3.5  The Expression of VEGF Receptors in the three maternal-fetal 
compartments. Panel A demonstrates VEGFR1 and B illustrates VEGFR2 mRNA 
expression in the placenta, placental bed and decidua parietalis. Panel C demonstrates 
VEGFR1 and VEGFR2 co-immunostaining in the placenta and placental bed and 
decidua parietalis. In the placental section VEGFR1 (green) staining can be seen in the 
cytotrophoblast columns (CC) and extravillous trophoblast (EVT). No VEGFR2 staining 
(red) was observed in the placental sections. Red blood cells (RBCs) auto-flouresce 
with both green and red dyes and can be seen (yellow) in the image. In the placental 
bed section both VEGFR1 (green) and VEGFR2 (red) staining were detected.VEGFR1 
staining was observed in the interstitial extravillous trophoblast (EVT) of the decidua 
basalis while VEGFR2 staining was limited to the decidual stroma. In comparison to 
the placenta and placental bed sections, there was  minimal VEGFR1 and VEGFR2 
staining in the decidua parietalis (Dp). 
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Figure 3.6  PROK1 and PROK1R expression in the Placenta, Placental Bed 
and Decidua Parietalis. Real-time PCR (Means ± SEM) showing PROK1 (A) and 
PROK1R (B) mRNA expression in the three maternal-fetal  tissues. (***), (**) and (*) 
signify p<0.001, p<0.01 and p<0.05 respectively. Panel (C) and (D) illustrate PROK1 
immunostaining in placental tissue. PROK1 protein (red) can be seen most abundantly 
expressed in the microvillous brush border (BB) of the syncytiotrophoblast layer(C). 
Morphological detail of the villous cytotrophoblast (cTB) and syncytiotrophoblast (sTB) 
cells are indicated. The PROK1 primary antibody was omitted in (D) (negative control) 
and no PROK1 immunostaining is demonstrable. The nuclei were stained with DAPI 
(blue).
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3.5   Discussion 
Understanding normal maternal-fetal dialogue is the first step in deciphering pregnancy-
related complications and can be valuable in optimizing assisted reproductive 
technology. In this chapter  the expression profiles of genes involved in trophoblast 
invasion and angiogenesis which are both essential for placentation was investigated. 
The expression of Kiss1, VEGF-A, PROK1 and their respective receptors GPR54, 
VEGFR1, VEGFR2 and PROK1R as well as the expression of MMP9 in the placenta, 
placental bed and decidua parietalis was examined. This study was conducted in 
a population of young healthy patients mostly in their second pregnancies with no 
pregnancy-related complications nor chronic medical conditions. 
Kisspeptin via its receptor, GPR54 has previously been shown to be an important role 
player in tumour metastasis suppression and trophoblast invasion. Kiss1, kisspeptin 
and GPR54 have never been investigated across maternal-fetal tissues, in particular the 
maternal placental bed and decidua parietalis. Strikingly high Kiss1 gene expression 
in the placenta and virtually no kisspeptin (protein) expression in the maternal tissues 
(placental bed and decidua parietalis) was observed. In contrast, GPR54 gene 
expression in the maternal tissues was only 50% less than that expressed in the 
placenta. Kisspeptin and GPR54 have previously been shown to inhibit trophoblast 
invasion in an autocrine/paracrine manner in primary human trophoblasts (Bilban et 
al., 2004). The maternal expression of GPR54 may therefore play a role in limiting 
excessive invasion of trophoblast cells in maternal tissues while high kisspeptin and 
GPR54 expression in the placenta may be involved in fetal autoregulation of invasion 
in maternal tissues (Fig. 3.7). This may suggest that the control of trophoblast invasion 
via the kisspeptin/GPR54 pathway is primarily exercised at the fetal level and is not 
only restricted to the first trimester but maintained to term. Kisspeptin could therefore 
have a role in the maintenance of placental invasive homeostasis until term. Another 
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possibility is that invasive capacity may also be controlled at the maternal level via 
GPR54 paracrine signalling. Recently Taylor et al., 2014 demonstrated that kisspeptin 
inhibits trophoblast invasion via a mechanism of increased EVT adhesiveness. High 
MMP9 expression in the placenta was demonstrated and this likely increases the fetal 
ability to degrade extracellular matrix, in particular type IV collagen and enhances 
maternal tissue invasion. Kisspeptin downregulates MMP9 expression in various 
cancers  (Lee and Kim, 2009, Yan et al., 2001) and this may be the mechanism by 
which kisspeptin inhibits trophoblast invasion. Furthermore, Kiss1 has been shown 
to reduce MMP9 transcription by interfering with binding of NFkb to the MMP9 
promoter in a cell line model  (Yan et al., 2001). Downregulation of MMP9 expression 
is associated with poor fetal growth and maternal preeclampsia (Zhang et al., 2006, 
Qiao et al., 2005a, Zhang et al., 2011) most likely by a mechanism involving limited 
trophoblast invasion and poor transformation of maternal spiral arteries. These data 
demonstrate the importance of the expression of gelatinases (among other proteases) 
by the fetal compartment in sustaining healthy pregnancies.
VEGF-A mRNA expression was highest in the maternal compartment (placental bed), 
yet numerous studies have focused on VEGF expression in the placenta and more 
so in pathological pregnancies  (Sgambati et al., 2004, Padavala et al., 2006, Chung, 
2004, Akercan et al., 2008, Shiraishi et al., 1996, Gurel et al., 2003). Consistent with the 
RT-PCR findings, the VEGF-A protein expression was highest in the placental bed and 
decidua parietalis. Furthermore this study demonstrated that extravillous trophoblast 
(EVT) and Trophoblast Giant Cells (TGCs) express VEGF-A protein in the placental 
bed. A study using in-situ hybridization showed that macrophages in the maternal 
decidua  (Sharkey et al., 1993) expressed the highest VEGF-A mRNA however our 
studies detecting VEGF-A protein clearly showed localization to EVTs and minimal 
VEGF-A localization to macrophages. 
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Future studies investigating pregnancy pathologies should therefore focus on changes 
in VEGF-A expression the placental bed rather than in the placenta. When examining 
VEGF receptor mRNA expression, the expression of VEGFR1 mRNA was  found to be 
highest in the placenta while that of VEGFR2 was highest in the maternal placental 
bed and decidua. VEGFR1 also known as the ‘‘decoy’’ receptor, is thought to bind 
to VEGF-A and thus scavenge and reduce the amount of bioavailable VEGF-A to 
bind to VEGFR-2 (which mediates its angiogenic and mitogenic effects)  (Kendall and 
Thomas., 1993, Park et al., 1994). Low VEGF-A mRNA and protein and high VEGFR1 
mRNA levels were observed in the placenta. VEGF-A may (via interaction with VEGFR1) 
be suppressed in the placenta while VEGFR2 mediates the angiogenic and mitogenic 
effects of VEGF-A in the maternal placental bed. Interestingly immunohistochemical 
staining for VEGFR1 protein was strong in extravillous trophoblast (cytotrophoblast 
columns in the placenta and interstitial trophoblast in the placental bed). 
Could this possibly be a mechanism by which these invading ‘‘fetal’’ cells suppress 
maternal angiogenesis in favour of their own angiogenic enhancement? Previously 
high expression of VEGFR1 both in the placenta and circulation (sFLT1) of pregnant 
women has been reported and was thought to regulate the action of VEGF-A in 
successful pregnancies  (Clark et al., 1998). On the other hand, both VEGF-A and 
VEGFR2 protein expression are reduced in the placentae of first trimester miscarriages 
compared to healthy controls (Vuorela et al., 2000). Furthermore both VEGF as well 
as VEGF receptor knockout mice result in embryonic demises (Carmeliet et al., 1996, 
Fong et al., 1995, Shalaby et al., 1995). This indicates the importance of VEGF-
mediated vasculogenesis and angiogenesis in early pregnancy. The findings from this 
study suggest that VEGF-A may be more important in the placental bed than the 
placenta in healthy human pregnancies at term. This would imply the potential role of 
a different angiogenic factor other than VEGF in maintaining placental angiogenesis 
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after de novo vasculogenesis is mediated by VEGF in early pregnancy.
Employing RT-PCR, this study has demonstrated that both the mRNA expression of 
PROK1 and PROK1R were highest in the placenta while that of its corresponding 
angiogenic factor, VEGF-A was highest in the placental bed. PROK1 and its cognate 
receptor PROK1R have recently been shown to be important tissue-specific role 
players in the angiogenesis of steroidogenic organs like the ovary, testis, adrenal and 
placenta (LeCouter et al., 2001). The action of PROK1 is thought to be complementary 
to that of VEGF in these tissues. PROK1 has also been shown to be important in 
enhancing maternal-fetal  dialogue in receptive endometrium (Evans et al., 2009) and 
thus likely to be important in early pregnancy health. 
By employing immunohistochemical analysis on first trimester placental tissue another 
study demonstrated the differential expression of VEGF and PROK1 in the placenta, 
with the former being expressed in the cytotrophoblast and EVT cells whilst the 
latter was distinctly expressed in the syncytiotrophoblast (Hoffmann et al., 2006). Of 
importance, this study found no PROK1 immunostaining in extravillous trophoblast. The 
same group also demonstrated differential placental expression of these angiogenic 
factors depending on gestation, with PROK1 and PROK1R increasing between 8 and 
10 weeks of gestation while VEGF mRNA remained unaltered throughout the first 
trimester. They concluded that this suggested complementary roles of PROK1 and 
VEGF in early pregnancy. 
Taken together with the findings of this study, these data are suggestive of distinct 
but complementary roles of these angiogenic factors where VEGF-A and its mitogenic 
receptor VEGFR2 may be mainly, but not exclusively, responsible for mediating maternal 
angiogenesis and spiral arteriolar transformation in the placental bed while PROK1 
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and PROK1R exclusively mediate placental villous angiogenesis in the fetus. VEGF-A 
likely plays a critical role in the initial stages of villous capillary vasculogenesis and 
early angiogenesis (as evidenced by lethality in VEGF receptor and ligand knockout 
embryos) and may facilitate integration of invasive EVT cells into the maternal vascular 
system. PROK1 on the other hand is potentially involved in maintaining angiogenesis 
after VEGF-A has initiated vascular events in early pregnancy.
Kisspeptin could in addition to inhibition of metalloprotease activity, accomplish its 
anti-metastasic effects through the suppression of angiogenesis via factors such 
as VEGF and PROK1. Kisspeptin has been shown to reduce Human Umbilical Vein 
Endothelial Cells (HUVEC) migration, invasion and tube formation via Specificity 
Protein-1 (SP1) mediated suppression of VEGF expression (Cho et al., 2009). In an 
in vitro study, kisspeptin was shown to inhibit both new vessel sprouting and tube 
structure formation in HUVECs in a dose dependant manner (Ramaesh et al., 2010). 
Kisspeptin could therefore limit fetal invasion both by suppressing placental MMP-9 
expression as well as inhibiting placental bed angiogenesis via the suppression of 
VEGF-A expression.
It should however be borne in mind that all the above findings are a description of 
the maternal-fetal interface at term. This is an acknowledged limitation of the study 
as a description of the molecular details of this interface in early pregnancy would 
provide more information on maternal-fetal dialogue. Nonetheless attempting such a 
study in early pregnancy could prove challenging firstly because true placental bed 
biopsies comprising decidua, extravillous trophoblast and myometrium might well 
prove difficult to attain in early pregnancy and secondly studies of such a nature (ie 
involving placental bed sampling) might be limited by ethical considerations.
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In summary this study has examined differential gene expression in both the fetal 
and maternal tissues of the maternal-fetal interface. Figure 3.7 is a depiction of the 
schematic representation of the anatomy of the maternal-fetal interface (Fig 3.7A) 
as well as the putative interactions of factors examined in this study at this interface 
(Fig 3.7B). The high fetal expression of Kiss1, GPR54 as well as MMP-9 which are 
all genes involved in invasion suggest that the control of invasive capacity (at least 
involving these genes) may predominantly be exercised at the fetal  level.
Examination of genes involved in angiogenesis revealed high expression of PROK1 
and PROK1R ligand-receptor pair in the fetus and high expression of VEGF-A and 
VEGFR2 ligand-receptor pair on the maternal side. VEGFR1, which is anti-VEGF, was 
highly expressed in the fetus. These findings may be suggestive of angiogenesis 
being  prokineticin-maintained in the placenta while maternal angiogenesis in the 
placental bed is mainly mediated by VEGF-A. Further studies will be required to 
explore the potential of this dual angiogenesis hypothesis. The findings could unveil 
the possible prophylactic use of VEGFR2 agonists in women with a predisposition 
for preeclampsia and the potential use of PROK1 agonists in the treatment of fetuses 
with growth restriction. Having defined the differential gene expression profiles across 
the maternal-fetal interface of healthy pregnancies, the next chapter compares these 
profiles with those from pathological pregnancies.
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Chapter 4 Reciprocal Expression of Angiogenic Regulators
4.1   ABSTRACT
Preeclampsia is a common pregnancy-associated disorder and is one of the leading 
causes of maternal and perinatal morbidity and mortality worldwide. The precise 
molecular mechanisms underlying the development of preeclampsia still remain 
unknown. Decreased trophoblast invasion and compromised maternal spiral arterial 
transformation have been implicated in its pathophysiology. In this chapter the 
expression of genes involved in trophoblast invasion (KISS1 and GPR-54 as well as 
angiogenic ligands (VEGF-A, PROK1) were investigated in the placenta, placental 
bed and decidua parietalis of normal and preeclamptic pregnancies. RT-PCR  was 
utilized to examine gene expression while immunohistochemistry and Western Blot 
were employed to investigate protein expression. Circulatory protein concentrations 
of kisspeptin, VEGF-A and PROK-1 were determined using ELISA. High kisspeptin 
protein expression was found in the placentae of pregnancies complicated by 
preeclampsia in comparison to healthy pregnancies. There was minimal Kiss-
1 mRNA and kisspeptin expression in the placental bed and decidua parietalis of 
both healthy and preeclamptic pregnancies. No difference was found in GPR-54 
mRNA expression across the maternal-fetal tissues of healthy and preeclamptic 
pregnancies. Prokineticin-1 mRNA expression was suppressed in the placentae and 
VEGF-A mRNA in the placental beds of preeclamptic pregnancies respectively. In 
addition, there was less VEGF-A protein expressed in the maternal tissues (placental 
bed and decidua parietalis) and cord sera of preeclamptic pregnancies in comparison 
to healthy controls.  No significant difference was found in mean maternal or cord 
serum EG-VEGF levels between healthy and preeclamptic pregnancies. Increased 
kisspeptin expression in the placenta along with suppressed pro-angiogenic gene 
(VEGF-A and Prokineticin-1) expression in maternal (placental bed) and placental 
components of the maternal-fetal interface respectively, is consistent with reduced 
trophoblast invasiveness as well as compromised angiogenesis and may represent a 
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molecular mechanism that explains the development of preeclampsia. 
4.2   INTRODUCTION
Preeclampsia is a pregnancy-specific condition that is typified by the development of 
new onset hypertension and proteinuria after 20weeks of pregnancy. The International 
Society for the Study of Hypertension in Pregnancy (ISSHP) defines hypertension as 
a systolic blood pressure ≥ 140mmHG and a diastolic blood pressure of ≥ 90mmHG. 
Significant proteinuria is defined as the presence of ≥ 300mg of urinary protein over 
a 24-hour period. More recently the ISSHP has revised the  diagnostic criteria for 
preeclampsia. (Tranquilli., 2013)  Preeclampsia is one of the more severe hypertensive 
disorders to complicate pregnancy (Davey and Macgillivray, 1986). 
Preeclampsia is commonly the leading cause of maternal and perinatal morbidity and 
mortality worldwide (Duley, 2009). The maternal and fetal complications associated 
with this disorder are a reflection of a generalised endothelial cell dysfunction with 
manifestations in various organs. The maternal complications related to preeclampsia 
are eclampsia (seizure disorder), pulmonary oedema, renal impairment, liver and 
coagulation defects not uncommonly presenting as the syndrome of Haemolysis 
Elevated Liver enzymes and Low Platelets - HELLP syndrome (Weinstein, 2005). The 
fetal complications which are an indication of placental dysfunction include IUGR, 
placental abruption and intrauterine death (Nisell et al., 2000).
The precise molecular pathophysiological mechanisms underlying this disorder still 
remain unclear. It is however largely acknowledged that there is inadequate spiral 
arterial transformation in the maternal placental beds of pregnancies complicated 
by preeclampsia (Brosens, 1977, Robertson et al., 1967b, Kim et al., 2003, Brosens 
et al., 2002, Moodley and Ramsaroop, 1989). It is also recognised that invasion of 
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the maternal decidua by extravillous trophoblast (EVT) cells as well as angiogenesis 
play crucial roles in the transformation of maternal spiral arteries from vessels of high 
resistance low capacity, to low resistance high capacity ones capable of supporting a 
healthy pregnancy (Kam et al., 1999).
Hence understanding the expression of genes involved in trophoblast invasion and 
angiogenesis across the maternal-fetal interface is critical in providing further insights 
about pregnancy-related pathologies such as preeclampsia. 
Kisspeptin inhibits trophoblast invasion in vitro (Bilban et al., 2004, Roseweir et al., 2012). 
Kisspeptin serum concentrations significantly increase as pregnancy progresses and 
considerably fall post-delivery (Horikoshi, 2003) whereas the placental expression of 
both Kiss-1 and GPR-54 are highest in the first trimester and lowest at term (Janneau 
et al., 2002, Bilban et al., 2004). Several  studies  have reported elevated Kiss-1 
mRNA and protein expression in trophoblasts (Qiao et al., 2005b) and placentae of 
pregnancies complicated by preeclampsia (Cartwright and Williams, 2012, Qiao et 
al., 2012, Zhang et al., 2006, Zhang et al., 2011). While one study reported increased 
GPR-54 expression in preeclampsia (Cartwright and Williams, 2012), the other found 
no difference in  placental GPR-54 mRNA and protein expression between healthy 
and preeclamptic pregnancies (Qiao et al., 2012). Also, decreased maternal serum 
kisspeptin levels in early pregnancy have been associated with development of 
preeclampsia (Armstrong et al., 2009, Cetkovic et al., 2012). Nonetheless no study 
has thus far examined the expression of kisspeptin and GPR-54 across maternal-fetal 
tissues and circulation more so in the context of preeclampsia.
Recent data suggests that kisspeptin may also inhibit metastasis via restriction of 
angiogenesis (Ramaesh et al., 2010, Cho et al., 2009). The simultaneous maternal-
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fetal expression of angiogenic ligands (VEGF-A and PROK-1) and kisspeptin in both 
tissue and circulation have never been investigated in pregnancies complicated by 
preeclampsia. The study hypothesis was that the expression of these factors would 
be different across the maternal-fetal interphase as well as maternal-fetal circulations 
of healthy and preeclamptic pregnancies. 
In this chapter the gene and protein expression of KISS1, GPR-54 and angiogenic 
ligands, VEGF-A and PROK1 were examined across the maternal-fetal tissues of both 
healthy and preeclamptic pregnancies. In addition, both maternal and cord circulatory 
levels of these proteins were concurrently examined in healthy as well as preeclamptic 
pregnancies.
4.3   METHODS
4.3.1   Study Participants
All patients recruited had elective caesarean section deliveries in the absence of 
labour. The inclusion criteria for the control arm of the study were healthy patients with 
singleton pregnancies undergoing elective caesarean section. Patients were excluded 
from the control arm of the study if they were in labour, had multiple pregnancies, had 
more than one previous caesarean section, had pregnancy-specific complications such 
as gestational diabetes, gestational hypertension, placenta praevia, preeclampsia, 
and intrauterine growth restriction. In addition, underlying chronic medical disorders 
such as preexisting diabetes or chronic hypertension were also exclusion criteria for 
the study. Patients in the control arm of the study were the same cohort as those 
described in Chapter 3. 
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The inclusion criteria for the experimental arm were patients with singleton pregnancies 
and a diagnosis of preeclampsia who were having elective caesarean delivery. 
Preeclampsia was defined as new-onset hypertension (diastolic blood pressures 
of ≥ 90mmHg on two separate occasions, 6 hours apart or  ≥ 100mmHg on one 
occasion) and significant proteinuria (24 hour protein collection ≥ 300mg).  Patients 
who were in labour, had multiple pregnancies, had more than one previous caesarean 
section, gestational diabetes, gestational hypertension, placenta praevia, as well as 
patients with pre-existing medical disorders were excluded from the experimental arm 
of the study. In addition, patients who had chronic hypertension with superimposed 
preeclampsia were excluded from the study. 
4.3.2  Tissue Sampling 
The placenta and placental bed were sampled at elective caesarean section using a 
technique previously described (Pijnenborg et al., 1991). Briefly, prior to delivery of 
the placenta, juxtaposed sections of the placenta and placental bed were marked 
by placing a needle and suture from the placenta and traversing the uterine wall. 
The central zones of the placenta (rather than peripheral) were marked. A core of the 
placental tissue around the suture (which contains the fetal surface) was then sampled 
and the rest of the placenta delivered. The section of the placental bed where the 
sampled placenta was resident was identified with the aid of the remaining suture and 
biopsied. The adequacy of the sampled placental bed was confirmed for presence of 
trophoblast, myometrium and spiral arteries by an independent histopathologist. In 
addition, the decidua parietalis which has no involvement in placentation (negative 
control) was sampled. (See Fig 1.3)
Collected tissue samples were first homogenized using a fine scalpel and equitably 
divided into three portions. The first portion was collected for RNA extraction while 
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the second and third portions were utilised for protein extraction and preparation of 
wax-embedded tissue blocks respectively. In addition maternal and cord blood were 
simultaneously taken at the time of delivery. The blood samples were centrifuged at 
10 000 rpm for 10 minutes to obtain serum which was subsequently frozen.
 
4.3.3  RNA Extraction, cDNA Synthesis and RT-PCR 
For gene expression studies, RNA extraction, cDNA synthesis and RT-PCR were 
conducted as previously described in Chapter Two. The Genebank accession 
numbers of the genes investigated are as follows: KISS1 (NM_002256), GPR-54 
(NM_032551), VEGF-A (NM_001171623) and PROK1 (NM_032414). Primer/Probe 
pairs corresponding to these genes (Sigma® Pharmaceuticals) were utilised (Table 
4.1) in the presence of the Taqman® Mastermix. 18S ribosomal RNA was utilized as 
internal control and gene expression was quantified relative to the same reference 
cDNA used for all RT-PCR studies. 
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Table 4.1   Primers and Probe Sequences used for Real-Time (RT) PCR Reactions II
10GPR54 Forward Primer 5’-GGTGCTGGGCGACTTCAT-3’
GPR54 Reverse Primer 5’-CACACTCATGGCGGTCAGAGT-3’
GPR54 Probe
5’-[FAM]-TGCAAGTTCGTCAACTACATCCAGCAGG-[TAM-
RA]-3’
11Kiss1 Forward Primer 5’-GGCAAGCCTCAAGGCACTT-3’
Kiss1 Reverse Primer 5’-GGAAAAGCAGTAGCTGCCAAGA-3’
Kiss1 Probe
5’-[FAM]-TGCCTCTTCTCACCAAGATGAACTCACTGG-[TAM-
RA]-3’
12PROK1 Forward Primer 5’-GTG CCA CCC CGG CAG-3’
PROK1 Reverse Primer 5’-AGC AAG GAC AGG TGT GGT GC-3’ 
PROK1 Probe
5’-[FAM]-ACA AGG TCC CCT TCT TCA GGA AAC GCA-[TAM-
RA]-3’ 
13VEGF Forward Primer 5’-TAC CTC CAC CAT GCC AAG TG-3’
VEGF Reverse Primer 5’-TAG CTG CGC TGA TAG ACA TCC A-3’
VEGF Probe
5’-[FAM]-ACT TCG TGA TGA TTC TGC CCT CCTCCT T-[TAM-
RA]-3’
1418S Forward Primer 5’-CGG CTA CCA CAT CCA AGG AA-3’
18S Reverse Primer 5’-GCT GGA ATT ACC GCG GCT -3’
18S Probe 5’-[VIC]-TGC TGG CAC CAG ACT TGC CCTC -[TAMRA]-3’
4.3.4 Protein Expression Studies 
Western blot analysis was performed as previously detailed for VEGF-A (Chapter 2). 
Immunohistochemical studies were conducted for kisspeptin protein content and 
ELISA was utilized to determine circulatory protein levels for kisspeptin-10, VEGF-A 
and PROK-1 as previously described. 
4.3.4.1   Semi-quantitative analysis of kisspeptin immunostaining 
 The slides were evaluated for areas of maximum kisspeptin staining and tile scans 
of these areas were captured. The extent of slide staining was semi-quantitatively 
assessed by employing the H-score (Akercan et al., 2008). A modified version 
of the H-score was utilised according to the equation, Mod H-score = ∑ (I x PPV), 
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where I represents (Intensity of staining), ∑ (the sum of) and PPV the (Percentage of 
Placental Villi that stain that intensity). The intensity of staining (I) was quantified as 
0 (no staining), +1 (weak staining), +2 (moderate staining), +3 (strong but patchy or 
incomplete villous staining) and 4+ (very strong and complete villous staining). The 
modified H-score therefore represents the sum of (∑) the percentage of placental villi 
staining a particular intensity.
 
4.3.5   Statistical Analysis
The Mann-Whitney test was employed to compare tissue mRNA transcript expression 
as well as differences in circulating protein levels between healthy and preeclamptic 
pregnancies. The statistical package utilized was GraphPad Prism version 5.00 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. 
Statistical significance was set at p < 0.05. 
4.4   RESULTS
4.4.1   Clinical Parameters
Thirty healthy control patients and nineteen patients with preeclampsia were recruited. 
Patients with preeclampsia were of a younger age, had lower gravidity and had  lower 
gestational ages in comparison to healthy controls. The gravidity was higher in control 
patients  in comparison to preeclamptic pregnancies. The parity was comparable 
between the two groups.  All the demographic data are summarized in Table 4.2
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Table 4.2     Patient Data
Healthy (N=30) Preeclampsia (N=19) P value
Age (yrs) 28.47 ± 0.87 25.00 ± 1.31 0.0378*
Gravidity 2.43 ± 0.18 1.90  ±  0.20 0.0464*
Parity 1.10 ± 0.16 0.68  ± 0.15 0.0934
Gestation (wks) 38.03 ± 0.06 32.95 ± 0.53 < 0.0001***
(***) and (*) signify p<0.001 and P<0.05 respectively
4.4.2 KISS1 gene and protein expression across the maternal-fetal 
interface of healthy and preeclamptic pregnancies.
The expression of KISS1 mRNA transcript in the placenta, placental bed and decidua 
parietalis obtained from both healthy pregnancies and pregnancies complicated 
by preeclampsia was determined. There was higher KISS1 mRNA expression in 
the placentae of both healthy and preeclamptic pregnancies in comparison to the 
placental bed and decidua parietalis (Figure 4.1). There was no difference in KISS1 
mRNA expression in the placenta, placental bed and decidua parietalis of preeclamptic 
in comparison to healthy pregnancies.
Immunohistochemical methods were employed to examine kisspeptin expression in 
the placentae, placental beds and decidua parietalis  of healthy and preeclamptic 
pregnancies (Figure 4.2). There was no kisspeptin immunoreactivity in the placental 
bed and decidua parietalis of both healthy and preeclamptic pregnancies. In the 
placenta, kisspeptin immunostaining was localized to the villous syncitiotrophoblast 
and cytotrophoblast cell layers. There was individual variability in percentage and 
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intensity of villous staining in both healthy (Figure 4.2A) and preeclamptic (Figure 
4.2B) pregnancies. A more intense and complete kisspeptin immunostaining was 
observed in the syncitio- and cytotrophoblast layers of preeclamptic in comparison 
to healthy pregnancies (Figure 4.2B). The semi-quantitative immunohistochemical 
scores (modified H-scores) were significantly higher in preeclamptic when compared 
to healthy placentae (Figure 4.2C), indicating higher placental kisspeptin content in 
preeclampsia.
4.4.3 GPR-54 mRNA transcript expression across the maternal-fetal 
interface of healthy and preeclamptic pregnancies.
Next the level of GPR-54 mRNA across maternal-fetal tissues was determined using 
RT-PCR. There was no difference in GPR-54 mRNA expression between the placenta, 
placental bed and decidua parietalis of healthy and preeclamptic pregnancies (Figure 
4.4). 
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Figure 4.1  Relative Kiss1 transcript expression across the maternal-fetal interface of healthy and 
preeclamptic pregnancies. Relative Kiss1 mRNA expression in the Placenta, Placental Bed and 
Decidua Parietalis of Healthy (blue bars) and Preeclamptic (red bars) Pregnancies. mRNA 
expression was quantified relative to 18S RNA by RT-PCR. 
Figure 4.1  Relative Kiss1 transcript expression across the maternal-fetal interface 
of healthy and preeclamptic pregnancies. Relative Kiss1 mRNA expression in the 
Placenta, Place tal Bed and Decidua Parietalis of Healthy (blue bars) and Preeclamptic 
(red bars) Pregnancies. mRNA expression was quantified relative to 18S RNA by RT-
PCR. 
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114
Immunohistochemical Analysis of Kisspeptin Expression in the
Placentae of Healthy and Preeclamptic Pregnancies
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Figure 4.2(A-C) represents immunohistochemical expression of kisspeptin protein in the placentae of 
both Healthy (A) and Preeclamptic Pregnancies (B). Each image in the figures depicts a tile scan of the 
placenta obtained from a single patient. Patients were denoted numbers preceded by alphabets “C”
signifying (Control) and “P” (Preeclampsia). Each tile scan is representative of the strongest 
immunohistochemical staining on the slide. The tile scans show kisspeptin staining (green fluorescence) 
of villous syncytiotrophoblasts (vST). Alpha smooth muscle actin (α-SMA) was used as positive control 
for slide staining and can be seen staining vascular smooth muscle within the placental villi (yellow).
The nuclei were stained with DAPI (blue). Panel C is a graphical representation of H-scores between 
healthy (blue) and preeclamptic (red) pregnancies. 
C 
Figure 4.2 (A-C) represents immunohistochemical expression of kisspeptin protein 
in the placentae of both Healthy (A) and Preeclamptic Pregnancies (PET) (B). Each 
image in the figures depicts a tile scan of the placenta obtain d from  single pati nt. 
Patients were denoted numb rs preceded by l tters “C” signifying (Control) a d “P” 
(Preeclampsia). Each tile scan is representative of the strongest immunohistochemical 
staining on the slide. The tile scans show kisspe tin staining (green fluorescence) of 
villous syncytiotrophoblasts (vST). Alpha smooth muscle actin (α-SMA) was used as 
positive control for slide staining and can be seen staining vascular smooth muscle 
within the placental villi (yellow). The nuclei were stained with DAPI (blue). Panel C is 
a graphical representation of H-scores between healthy (blue) and preeclamptic (red) 
pregnancies.
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An ELISA was used to quantify circulatory kisspeptin-10 levels in the maternal and 
cord sera of healthy and preeclamptic pregnancies (Figure 4.3). The mean circulatory 
kisspeptin-10 levels in the maternal and cord sera of healthy pregnancies were 1.66 
± 0.59 ng/ml and 2.03 ± 0.44 ng/ml respectively (mean ± SEM). In preeclamptic 
pregnancies, the corresponding levels were 0.58 ± 0.39 ng/ml in the maternal serum 
and 1.78 ± 0.38 ng/ml in the cord serum. There were no differences between the 
mean maternal and cord serum kisspeptin-10 concentrations in healthy pregnancies 
however in preeclamptic pregnancies there were significantly lower circulating 
maternal kisspeptin-10 levels when compared to cord levels.  In addition, the mean 
maternal circulatory kisspeptin-10 level in preeclamptic pregnancies was much lower 
in comparison to the maternal circulatory levels in healthy pregnancies.
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Figure 4.3 Circulatory kisspeptin-10 levels in the Maternal and Cord Sera of Healthy and
Preeclamptic Pregnancies. Kisspeptin-10 levels (ng/ml) in the maternal (plain bars) and cord sera
(pixelated bars) of healthy (blue) and preeclamptic (red) pregnancies as determined by ELISA. The
data is presented as means ± SEM. In healthy pregnancies, the mean maternal and cord serum
kisspeptin-10 levels were 1.66 ± 0.59 ng/ml and 2.03 ± 0.44 ng/ml while in preeclamptic pregnancies
they were 0.58 ± 0.39 ng/ml and 1.78 ± 0.38 ng/ml, respectively. 
Figure 4.3
Figure 4.3 Circulatory kisspeptin-10 levels in the Maternal and Cord Sera of 
Healthy and  Preeclamptic Pregnancies. Kisspeptin-10 levels (ng/ml) in the maternal 
(plain bars) and cord sera (pixelated bars) of healthy (blue) and preeclamptic (red) 
pregnancies as determined by ELISA. The data are presented as means ± SEM. 
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Figure 4.4 Relative GPR-54 transcript expression across the maternal-fetal interface of healthy 
and preeclamptic pregnancies. Relative GPR-54 mRNA expression in the Placenta, Placental 
Bed and Decidua Parietalis of Healthy (blue bars) and Preeclamptic (red bars) Pregnancies. 
mRNA expression was quantified relative to 18S RNA by RT-PCR. 
Western blot analysis was utilised to examine VEGF-A protein expression in the placenta, 
placental bed and decidua parietalis of healthy and preeclamptic pregnancies. There was less 
VEGF-A protein expressed in the maternal tissues (placental bed and decidua parietalis) of 
preeclamptic pregnancies when compared to healthy controls (Figure 4.5B), while expression 
levels in the placenta were similar.
Figure 4.4 
Figure 4.4 Relative GPR-54 transcript expression across the maternal-fetal 
interface of healthy and preeclamptic pregnancies.  Relative GPR-54 mRNA 
expression in the Placenta, Placental Bed and Decidua Parietalis of Healthy (blue bars) 
and Preeclamptic (red bars) Pregnancies. mRNA expression was quantified relative to 
18S RNA by RT-PCR. 
Western blot analysis was utilised to examine VEGF-A protein expression in the 
placenta, placental bed and decidua parietalis of healthy and preeclamptic pregnancies. 
There was less VEGF-A protein expressed in the maternal tissues (placental bed and 
decidua parietalis) of preeclamptic pregnancies when compared to healthy controls 
(Figure 4.5B), while expression levels in the placenta were similar.
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4.4.4 VEGF-A gene and protein expression across the maternal-fetal 
interface of healthy and preeclamptic pregnancies.
RT-PCR was utilized to study VEGF-A mRNA transcript expression in the placenta, 
placental bed and decidua parietalis of healthy and preeclamptic pregnancies. The 
mean relative VEGF-A mRNA expression in the placenta, placental bed and decidua 
parietalis of healthy pregnancies were 0.15 ± 0.06, 0.71 ± 0.22 and 0.47 ± 0.13, 
respectively (Figure 4.5A). However in pregnancies complicated by preeclampsia, the 
mean relative VEGF-A mRNA expression in the same tissues were significantly lower. 
The VEGF-A mRNA transcript levels in preeclamptic pregnancies were 7-fold less in 
the placenta 0.02 ± 0.01, 11-fold less in the placental bed 0.06 ± 0.01 and 5-fold less 
in the decidua parietalis 0.09 ± 0.04 when compared to healthy pregnancies (Figure 
4.5A). 
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Figure 4.5.  The Expression of VEGF-A transcript and protein in the Placenta, 
Placental bed and Decidua parietalis in Healthy and Preeclamptic Pregnancies. (A) 
depicts  the expression of VEGF-A mRNA transcript in the Placenta, Placental bed 
and Decidua Parietalis of Healthy and Preeclamptic Pregnancies. mRNA expression 
was determined using RT-PCR relative to 18S ribosomal RNA. Data are presented as 
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means ± SEM. (B) depicts a representative western blot analysis of  VEGF-A protein 
content in the Placenta(P), Placental Bed (B) and Decidua Parietalis (D) of healthy 
(C013) and preeclamptic (P018) pregnancies. VEGF-A bands are visible at 20kD and 
40kD (homo-dimer). The red squares demarcate the maternal tissues (Placental Bed 
and Decidua Parietalis).
Next, circulatory VEGF-A levels in the maternal and cord sera of healthy and 
preeclamptic pregnancies were determined using a human VEGF-A sandwich ELISA. 
VEGF-A concentrations were interpolated from a standard curve of known VEGF-A 
concentrations as a function of optical density at 450nm (Figure 4.6). The ‘goodness 
of fit’ r2 value for the standard curve was 0.9874.
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Figure 4.6 Human VEGF-A ELISA Standard Curve shows a standard curve of known VEGF-
A concentrations (dots) in (pg/ml) as a function of optical density at 450nm (OD 450nm) 
determined using a human VEGF-A sandwich ELISA. The ‘goodness of fit’ (straight line) r2 value 
for the standard curve was 0.9874.  
 
 
 
In healthy pregnancies the mean maternal serum VEGF-A concentrations (mean ± SEM) were (43 
± 14 fg/ml), while the cord levels were significantly higher (852 ± 294 fg/ml) whereas in 
preeclamptic pregnancies there was no difference between mean maternal (74 ± 44 fg/ml) and cord 
serum VEGF-A  concentrations (240 ± 132 fg/ml) (Figure 4.7A). More importantly, the mean cord 
serum VEGF-A concentrations in preeclamptic pregnancies (240 ± 132) fg/ml were significantly 
lower when compared to mean cord serum levels in healthy pregnancies (852 ± 294) fg/ml (Figure 
4.7B).         
 
4.4.5 PROK-1 (EG-VEGF) transcript and protein expression across the maternal-fetal 
interface of healthy and preeclamptic pregnancies. 
Figure 4.6 Human VEGF-A ELISA Standard C r  s ows a standard curve of known 
VEGF-A concentrations (dots) in (pg/ml) as a function of optical density at 450nm (OD 
450nm) determined using a human VEGF-A sandwich ELISA. The ‘goodness of fit’ 
(straight line) r2 value for the standard curve was 0.9874. 
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Figure 4.7 Serum VEGF-A concentrations in maternal and cord sera of healthy 
and preeclamptic pregnancies  This figure depicts the mean maternal (plain bars) and 
cord (pixelated bars) serum VEGF-A concentrations in healthy (blue) and preeclamptic 
(red) pregnancies. (A) shows the mean VEGF-A concentrations in the cord and maternal 
serum of healthy pregnancies (B) depicts the mean maternal and cord serum VEGF-A 
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concentrations in pregnancies complicated by preeclampsia. (C) illustrates differences 
in cord serum VEGF-A concentrations of healthy and preeclamptic pregnancies. 
The mean cord serum VEGF-A concentrations in preeclamptic pregnancies were 
significantly lower in comparison to the mean cord serum concentrations of healthy 
pregnancies (p=0.0115).
In healthy pregnancies the mean maternal serum VEGF-A concentrations (mean ± 
SEM) were 43 ± 14 fg/ml, while the cord levels were significantly higher (852 ± 294 fg/
ml) whereas in preeclamptic pregnancies there was no sigificant difference between 
mean maternal (74 ± 44 fg/ml) and cord serum VEGF-A  concentrations 240 ± 132 fg/
ml (Figure 4.7A and B). More importantly, the mean cord serum VEGF-A concentrations 
in preeclamptic pregnancies 240 ± 132 fg/ml were significantly lower when compared 
to mean cord serum levels in healthy pregnancies 852 ± 294 fg/ml (Figure 4.7C).        
4.4.5 PROK-1 (EG-VEGF) transcript and protein expression across the 
maternal-fetal interface of healthy and preeclamptic pregnancies.
RT-PCR was utilized to study PROK-1 mRNA transcript in the placenta, placental bed 
and decidua parietalis of healthy and preeclamptic pregnancies. The mean PROK-
1 mRNA expression levels in the placenta, placental bed and decidua parietalis of 
healthy pregnancies were 3.851 ± 0.861, 1.132 ± 0.272 and 1.329 ± 0.786, respectively 
(Figure 4.8A). In pregnancies complicated by preeclampsia, the mean PROK-1 mRNA 
levels in the placenta, placental bed and decidua parietalis were much lower and were 
0.037 ± 0.015, 0.063 ± 0.013 and 0.058 ± 0.029, respectively. There were significantly 
lower mean PROK-1 mRNA expression levels in the placenta (100-fold less), placental 
bed (17-fold less) and decidua parietalis (22-fold less) of pregnancies complicated 
by preeclampsia in comparison to those in healthy pregnancies (Figure 4.8A). The 
largest difference in PROK-1 mRNA expression between preeclamptic and healthy 
pregnancies was observed in the placenta. 
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A human immunosorbent assay was utilised to determine maternal and cord serum 
PROK1 concentrations in both healthy and preeclamptic pregnancies. The ‘goodness 
of fit’ r2 value for the standard curve was 0.9787 (Figure 4.8B). In healthy pregnancies, 
the EG-VEGF protein concentrations (mean ± SEM) in the cord sera (20.96 ± 5.04) 
pg/ml were significantly less than those observed in the maternal serum (54.80 ± 
10.95) pg/ml (Figure 4.8B). There was no difference in the mean maternal (43.12 ± 
9.25) pg/ml and cord serum (46.58 ± 29.92) pg/ml PROK-1 protein concentrations in 
pregnancies complicated by preeclampsia. When comparing healthy and preeclamptic 
pregnancies, no difference in mean maternal or cord serum PROK-1 levels was 
observed (Figure 4.8C).               
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Figure 4.8  Relative PROK-1 transcript and protein expression across the 
Maternal-Fetal Interface of Healthy and Preeclamptic Pregnancies. (A) represents 
the expression of PROK1 mRNA in the Placenta, Placental bed and Decidua Parietalis of 
Healthy (blue) and Preeclamptic (red) Pregnancies. mRNA expression was determined 
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using RT-PCR relative to 18S ribosomal RNA. Data are presented as means ± SEM. (**) 
and (***) signify p<0.01 and p<0.001 respectively. B) shows standard curve of known 
PROK-1 concentrations (dots) in (pg/ml) as a function of optical density at 450nm (OD 
450nm) determined using a human PROK-1 sandwich ELISA. The ‘goodness of fit’ 
(straight line) r2 value for the standard curve was 0.9787. (C) depicts mean maternal 
(plain bars) and cord (pixelated bars) serum PROK-1 concentrations in healthy (blue) 
and preeclamptic pregnancies (red). (D) shows mean cord serum (pixelated) PROK1 
levels in healthy (blue) and preeclamptic pregnancies (red). 
4.5  DISCUSSION 
KISS1 and its gene product (kisspeptins) have previously been demonstrated to inhibit 
trophoblast cell invasion (Bilban et al., 2004, Roseweir et al., 2012). Post-translational 
processing of the KISS1 gene results in kisspeptins of various lengths, ranging from 
the longest kisspeptin-145, kisspeptin-54 also known as metastin, kisspeptin-14, 
kisspeptin-13, to the shortest cleavage product kisspeptin-10.  Kisspeptins have 
been of particular interest in the study of preeclampsia because limited trophoblast 
invasion is thought to result in inadequate transformation of the spiral arteries which 
is the fundamental pathophysiology of the disease (Kam et al., 1999). KISS1 and 
kisspeptins have thus been studied both in the placenta and maternal circulation of 
pregnancies complicated by preeclampsia. Although studies have focused on different 
forms of kisspeptins, one study (Bilban et al., 2004) demonstrated kisspetin-10 to be 
the most physiologically relevant kisspeptin in the placenta.
This study revealed significantly elevated kisspeptin-10 protein and a trend towards 
increased KISS1 mRNA expression in the placentae of preeclamptic pregnancies. 
This is in keeping with a previous study which investigated KISS1 mRNA expression in 
trophoblasts isolated from patients with preeclampsia and healthy term pregnancies 
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(Qiao et al., 2005b). In that study, increased KISS1 mRNA and metastin (kisspeptin-54) 
expressed in trophoblasts isolated from placentae of patients with preeclampsia 
was observed and there was a correlation between expression levels and severity 
of disease. Recently, others have confirmed increased KISS1 mRNA expression in 
the placentae of preeclamptic pregnancies (Qiao et al., 2012, Zhang et al., 2011). In 
contrast, a few studies have reported decreased placental KISS1 mRNA expression 
in pregnancies complicated by preeclampsia (Qiao et al., 2005a, Cartwright and 
Williams, 2012). Nonetheless from a pathophysiological perspective, it is much 
more intuitive to envisage elevated placental KISS1 gene or protein expression in 
preeclamptic pregnancies as it explains the currently accepted aetiological mechanism 
of decreased trophoblast invasion. To the knowledge of the writer, no study has thus 
far investigated KISS1 mRNA expression in the maternal tissues (placental bed or 
decidua parietalis) of pregnancies complicated by preeclampsia. This study reports 
increased kisspeptin expression in preeclamptic placentae in comparison to placentae 
of normal pregnancies and no difference in placental bed or parietal decidua KISS1 
mRNA expression between healthy and preeclamptic pregnancies. 
Furthermore no difference in GPR-54 mRNA expression in the placenta, placental 
bed or decidua parietalis of healthy and preeclamptic pregnancies was observed. 
One study (Cartwright and Williams, 2012) recently reported increased GPR-54 
mRNA and protein expression in the placentae of preeclamptic patients. There is a 
discrepancy in the literature of the correlation between kisspeptin tissue expression 
levels and circulating kisspeptin concentrations. Therefore in this study the maternal-
fetal tissue KISS1 mRNA expression as well as circulatory kisspeptin concentrations 
were simultaneously examined in healthy and preeclamptic pregnancies. Despite 
the finding of increased kisspeptin expression in the placentae of pregnancies 
complicated by preeclampsia, there were decreased circulating kisspeptin levels in 
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the maternal serum of preeclamptic when compared to healthy pregnancies. Two 
other studies have previously reported decreased circulating kisspeptin levels in 
pregnancies complicated by preeclampsia. The one was a prospective study which 
described a positive correlation between low plasma kisspeptin levels in the second 
and third trimester of pregnancy and subsequent development of preeclampsia and 
gestational diabetes (Cetkovic et al., 2012). In this study, low kisspeptin levels were 
thought to correlate well with placental dysfunction and adverse perinatal outcomes. 
The other was a retrospective case-control study which reported low serum 
kisspeptin-10 concentrations at 16-20 weeks gestation in pregnancies complicated 
by preeclampsia and intrauterine growth restriction (Armstrong et al., 2009). In fact low 
circulating kisspeptin levels have not only been associated with preeclampsia but also 
with early pregnancy bleeding (Kavvasoglu et al., 2012), intrauterine growth restriction 
(Armstrong et al., 2009, Smets et al., 2008) and gestational diabetes (Cetkovic et al., 
2012) such that low circulating kisspeptin levels could potentially be utilised as a 
surrogate marker for placental dysfunction. 
 
Diminished circulating kisspeptin levels in preeclampsia could be explained by 
compromised endovascular invasion resulting in a reduced amount of kisspeptin-
secreting trophoblast cells in the maternal spiral arteries. In support of this hypothesis 
is the detection of decreased circulating KISS1 mRNA in the maternal whole blood of 
pregnancies complicated by preeclampsia (Farina et al., 2006). Against this postulate 
is the reported increased incidence of fetal trafficking in pregnancies complicated by 
preeclampsia (Hahn., 2002). With increased trophoblast debris in circulation which 
is a feature of fetal trafficking, one would expect elevated levels of kisspeptins in 
circulation in preeclampsia.
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Failure of adequate transformation of maternal spiral arteries is thought to be the 
fundamental pathophysiological mechanism underlying the development not only 
of preeclampsia but also of a range of pregnancy-related complications including 
intrauterine growth restriction, miscarriage and preterm labour (Brosens, 2011). 
Central to maternal vascular transformation is the expression of angiogenic ligands, 
in particular VEGF in the maternal placental bed. It is therefore not surprising that 
VEGF, specifically VEGF-A has been extensively studied in pregnancies complicated 
by preeclampsia. Many studies have examined the expression of VEGF in the 
placenta while others have investigated its expression in circulation, however very 
few studies have explored its expression both in circulation and maternal-fetal tissues 
simultaneously.
This study focused on the maternal-fetal expression of VEGF-A transcript at tissue 
level (placenta, placental bed and decidua parietalis) as well as circulating protein 
concentrations in the maternal and cord sera of preeclamptic and healthy pregnancies. 
At tissue level, decreased VEGF-A mRNA and protein expression in the placenta, 
placental bed and decidua parietalis of preeclamptic pregnancies were found. Of the 
three maternal-fetal tissues investigated, the most significant difference in VEGF-A 
mRNA expression between healthy and preeclamptic pregnancies was in the 
maternal placental bed. There are at least eleven studies that have investigated VEGF 
mRNA expression in the placentae of preeclamptic pregnancies. Of these studies, 
five (Andraweera et al., 2012, Cooper et al., 1996, Govender et al., 2012, Park et al., 
2010, Sgambati et al., 2004) reported decreased mRNA expression in placenta, three 
(Tsatsaris et al., 2003, Zhou et al., 2010, Chung, 2004) increased expression while the 
other three studies (Han et al., 2012, Ranheim et al., 2001, Toft et al., 2008) reported 
no difference in placental VEGF mRNA expression between preeclamptic and normal 
pregnancies (Table 4.3). Studies examining placental VEGF-A protein expression in 
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preeclampsia are also conflicting. Seven studies have investigated differences in 
VEGF protein expression in the placentae of healthy and preeclamptic pregnancies. 
Three of these studies (Lyall et al., 1997, Milovanov et al., 2008, Wang et al., 2010) 
found decreased placental VEGF protein expression in preeclamptic pregnancies, 
three (Akercan et al., 2008, Bosco et al., 2010, Toft et al., 2008) reported increased 
expression and one study (Chung, 2004) found no difference in placental VEGF-A 
protein expression between healthy and preeclamptic pregnancies purely for the 
purpose of comparison. 
Invasion of trophoblast cells into maternal tissues and transformation of the spiral 
arteries occur in the placental bed. Thus, the molecular processes transpiring in 
the placental bed are pivotal to the understanding of pregnancy physiology and 
pathophysiology. In this study markedly suppressed placental bed VEGF mRNA 
expression was found in preeclamptic pregnancies. In concordance with the current 
study, one study (Kim et al., 2012) recently reported decreased VEGF mRNA in the 
placental beds of preeclamptic pregnancies while the other studies (Ranheim et al., 
2001, Tsatsaris et al., 2003) reported no difference in placental bed mRNA expression 
between preeclamptic and healthy pregnancies. Of the four studies that examined 
differences in VEGF protein expression in the placental bed of healthy and preeclamptic 
pregnancies, three studies (Cirpan et al., 2007, Kim et al., 2012, Milovanov et al., 
2008) found decreased VEGF protein expression in preeclampsia while the third study 
(Vuorela and Halmesmaki, 2006) reported no difference in expression (Table 4.3). 
Hence when evaluating VEGF-A tissue expression in the placentae of preeclamptic 
pregnancies, most studies reported decreased VEGF-A mRNA expression and there 
was minimal concordance between studies examining VEGF-A protein expression. In 
addition, most studies examining placental bed expression in preeclamptic pregnancies 
reported decreased VEGF-A protein expression and only one study found decreased 
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VEGF-A mRNA expression. It is very tempting to postulate decreased VEGF-A protein 
expression in the placental bed as the primary trigger of preeclampsia but this could 
equally be secondary to poorly vascularised maternal tissues.
This study found lower circulating maternal VEGF-A protein concentrations in 
comparison to cord levels in both healthy and preeclamptic pregnancies. However, the 
cord VEGF-A concentrations in preeclampsia were significantly lower in comparison 
to those in healthy pregnancies. Quite the opposite to the present findings, one 
similar study (Salama et al., 2011) reported  higher maternal VEGF-A concentrations 
when compared to cord levels in both healthy and preeclamptic pregnancies and 
significantly higher cord VEGF concentrations  in preeclamptic pregnancies.
No difference in circulating maternal VEGF-A protein concentrations between healthy 
and preeclamptic pregnancies was observed. There are at least eleven studies that 
examined circulating maternal VEGF concentrations in preeclamptic pregnancies. 
Five of these studies (Laskowska et al., 2008, Livingston et al., 2000, Purwosunu 
et al., 2009, Semczuk-Sikora et al., 2007, Zhou et al., 2010) reported decreased 
maternal VEGF concentrations in preeclamptic pregnancies, four (Bussen et al., 2003, 
Salama et al., 2011, Sharkey et al., 1996, Tsatsaris et al., 2003) reported increased 
concentrations and two (Han et al., 2012, Sezer et al., 2012) reported no difference 
in circulating maternal VEGF concentrations between preeclamptic and healthy 
pregnancies. There seems to be no clear agreement amongst the studies reporting on 
circulating maternal VEGF levels in preeclamptic pregnancies.
Lastly, PROK-1 has recently been shown to be an important placental angiogenic 
factor crucial for early placental villous development facilitated by stimulation of 
cytotrophoblast cells and proliferation of endothelial cells (Brouillet et al., 2013). PROK-
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1 is also important in maintaining early fetal-maternal interactions (Evans et al., 2009). 
The current study found significantly decreased PROK-1 mRNA expression levels in 
the placenta, placental bed and decidua parietalis of pregnancies complicated by 
preeclampsia. Furthermore, the greatest difference in mRNA expression between 
preeclamptic and healthy pregnancies was in the placenta and not in the placental 
bed as was observed with VEGF mRNA expression. Previously no difference in PROK1 
expression was found between the placentae of preeclamptic and healthy pregnancies 
(Chung, 2004). Interestingly, in healthy pregnancies maternal-cord circulatory studies 
showed lower maternal VEGF-A protein levels in comparison to cord levels and higher 
maternal PROK1 protein concentrations when compared to cord levels. This suggests 
different and possibly complementary roles of these angiogenic factors as previously 
reported (Hoffmann et al., 2007) , in pregnancy health even at term.
This difference in topographical expression between two angiogenic factors within 
the context of pathological pregnancies may shed more light about their relative 
physiological importance across the maternal-fetal interface. Based on the tissue 
expression studies comparing health and preeclampsia conducted in this study, it 
seems tempting to consider VEGF-A as the maternally significant angiogenic factor 
chiefly responsible for transformation of the spiral arteries within the placental bed, 
while EG-VEGF is the placentally vital angiogenic factor mainly responsible for villous 
angiogenesis. 
This study has a few limitations, firstly it was conducted in later pregnancy and events 
such as trophoblast invasion and angiogenesis are best studied in early pregnancy 
when placentation is most critical in determining pregnancy outcome. However, due 
to ethical considerations, true placental bed tissue biopsies (with representative 
interstitial trophoblast, myometrium and spiral arteries) would be difficult to obtain 
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in early pregnancy and the prediction of later development of preeclampsia during 
this period still remains a challenge. Secondly, due to risk of serious maternal and 
fetal complications often associated with preeclampsia, delivery prior to term is 
often recommended. It would therefore be ethically imprudent to obtain gestationally 
matched tissue from otherwise uncomplicated healthy pregnancies (Hahn., 2002). The 
advantage of studying late gestation is that the effects of kisspeptin on placentation, 
invasion and angiogenesis may be different in late in comparison to early gestation. In 
addition studying kisspeptin expression and circulatory levels in late pregnancy may 
be important in indicating villous.
Further studies need to investigate the role of other angiogenic factors like placental 
growth factor (PGF), endoglin, angiopoetins as well as angiogenic receptors such as 
VEGFR1, VEGFR2 and angiopoetin receptors across the maternal-fetal interface of 
health and disease. A better understanding of their role and the interplay among them 
may potentially reveal targeted opportunities for the development of drugs aimed at 
alleviation or prophylaxis of preeclampsia and/or intrauterine growth restriction.
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Table 4.3   Studies Investigating Maternal and Fetal Tissue VEGF 
expression in Preeclamptic Pregnancies  
Study mRNA Protein Method
Placenta
Akercan 2008 ↑­ IH
Andraneera 2012 ↓ RT-PCR
Bosco 2010 ­↑ IH
Chung 2004 ­↑ ↔ RT-PCR/WB
Cooper 1996 ↓ RT-PCR
Govender 2012 ↓ RT-PCR
Han 2012 ↔ RT-PCR
Lyall 1997 ↓ IH
Milanov 2008 ↓ IH
Park 2010 ↓ RT-PCR
Ranheim 2001 ↔ RT-PCR
Sgambati 2004 ↔ ­ RT-PCR/ IH
    ↓ (PET + HELLP)
Toft 2008 ↔ RT-PCR
Tsatsaris 2003 ­↑ RT-PCR
Wang 2010 ↓  WB
Zhou 2010 ­↑ RT-PCR
This study ↓ RT-PCR
Placental Bed
Cirpan 2007 ↓ IH
Kim 2012 ↓ ↓ RT-PCR/IH/WB
Milovanov 2008 ↓ IH
Ranheim 2001 ↔ RT-PCR
Tsatsaris 2003 ↔ RT-PCR
Vuorela 2006 ↔ IH
This study ↓ ↓ RT-PCR/WB
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Abbreviations: IH (Immunohistochemistry)
                           RT-PCR (Real-time Polymerase Chain Reaction)
                           WB (Western Blot)
                           PET (Preeclampsia)
                           HELLP ( Haemolysis, Elevated Liver Enzymes and Low Platelets)
                           ↑     Increased  Expression 
                           ↓     Decreased  Expression 
                          ↔    No Difference in Expression 
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5.1   Abstract
Normal placental development in early pregnancy is critical in determining a healthy 
pregnancy outcome. Angiogenesis is an indispensable component of normal 
placentation. VEGF-A plays a fundamental role in angiogenesis and mainly mediates 
its angiogenic effects via VEGF receptor -1 and -2 (VEGFR-1 and VEGFR-2). In order 
to study the role of kisspeptin on the mRNA expression of VEGF-A, VEGFR-1 and 
VEGFR-2 in normal and abnormal placentation, kisspeptin stimulation experiments 
were conducted on placental explants from healthy and preeclamptic pregnancies. 
RT-PCR  was utilized to study placental VEGF-A, VEGFR-1 and VEGFR-2 mRNA 
expression following tissue explant incubation with kisspeptin for various time-points 
over a 24-hour period. The stimulation results showed no effect of kisspeptin-10 
on the expression of VEGF-A, VEGFR-1 or VEGFR-2 mRNA. However in healthy 
pregnancies, kisspeptin stimulation resulted in non-significant suppression of placental 
mRNA expression of VEGF-A and VEGFR-2 at 8hours and VEGFR-1 at all time-points. 
Whereas in preeclamptic pregnancies placental stimulation with kisspeptin resulted 
in a non-significant up-regulation of VEGF-A mRNA expression at 8hours, VEGFR-2 
at all time-points. In summary kisspeptin stimulation had no effect on the expression 
of VEGF-A mRNA or its receptors. However observed trends towards contrasting 
angiogenic factor suppression in healthy placentae and up-regulation in preeclampsia 
may suggest different angiogenic regulatory roles by kisspeptin in pregnancy pathology 
and health. 
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5.2   Introduction
Angiogenesis is a process involving the development of new vessels from existing 
vessels (Carmeliet, 2005). The placenta is a highly vascular organ and mainly develops 
by branching angiogenesis (Reynolds and Redmer, 2001). Vascular endothelial growth 
factor (VEGF) plays a pivotal role in angiogenesis (Hoeben et al., 2004). VEGF has 
various subtypes (A-E) of which VEGF-A is the most predominant in the placenta (Clark 
et al., 1998b), in particular the VEGF-A 165 isoform. VEGF-A mediates its angiogenic 
effects principally via threonine kinase receptors VEGFR-1 and VEGFR-2 (Ferrara et 
al., 2003).
Kiss1 metastasis suppressor gene encodes kisspeptins (Kps) of various lengths (Kp-
154, -54, -13 and -10). Kisspeptin-10 is the most biologically active in the placenta 
and inhibits migration and invasion in primary trophoblast cultures (Bilban et al., 2004). 
Furthermore kisspeptin administration results in phenotypical suppression of vessel 
development in first trimester explants (Ramaesh et al., 2010). Our research group has 
recently demonstrated that kisspeptin-10 suppresses VEGF-A mRNA expression in 
first trimester primary trophoblast cultures (Francis et al., 2014).
 
Various studies including the work described in Chapter 4 have demonstrated elevated 
kisspeptin expression in preeclamptic placentae (Qiao et al., 2012, Qiao et al., 2005b, 
Zhang et al., 2011). The effects of kisspeptin stimulation however have never been 
compared between healthy and preeclamptic placental tissue. The objective of this 
study was to investigate the effects of kisspeptin-10 administration on transcript 
expression of key angiogenic factors namely VEGF-A, VEGFR-1 and VEGFR-2 in 
placental explants from healthy and preeclamptic pregnancies.
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5.3   Materials and Methods 
The study was approved by the Human Ethics Committee of the Faculty of Health 
Sciences, University of Cape Town (REF: 080/2008). Written informed consent was 
obtained from all study participants and the research was conducted according to 
the ethical principles of the Declaration of Helsinki (Bruce-Chwatt, 1965, 2001). The 
patients were counselled in their preferred language and were presented with Patient 
Information Leaflets (PILs) providing the details of the study. The comprehension of this 
information was always assessed and in cases of uncertainty, consent was withdrawn. 
Study participation remained the patient’s prerogative without any coercion and their 
decision not to participate did not compromise their further management and care. 
Furthermore recruitment to the study did not involve the patient’s clinical carers but 
members of the research team.
5.3.1   Study Participants
All patients recruited had elective caesarean section deliveries in the absence of labour. 
The inclusion criteria for the control arm of the study were healthy patients undergoing 
elective caesarean section for the indications of either previous caesarean section 
or fetal malpresentation. Patients were excluded from the control arm of the study 
if they were in labour, had more than one previous caesarean section, had multiple 
pregnancies, had pregnancy-specific complications such as gestational diabetes, 
gestational hypertension, placenta praevia, preeclampsia, intrauterine growth 
restriction. In addition, underlying chronic medical disorders such as preexisting 
diabetes or chronic hypertension were also an exclusion from the study. Patients were 
recruited from Groote Schuur Hospital which is a tertiary referral centre and Mowbray 
Maternity Hospital which is a secondary referral obstetric hospital in Cape Town, South 
Africa. The inclusion criteria for the experimental arm were patients with a diagnosis 
of preeclampsia who were having elective caesarean sections. Patients in labour, 
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patients who had two previous caesarean sections, gestational diabetes, gestational 
hypertension, placenta praevia, as well as patients with preexisting medical disorders 
were excluded from the experimental arm of the study. In addition, patients who had 
chronic hypertension with superimposed preeclampsia were excluded from the study.
5.3.2   Tissue Sampling and Specimen Collection
Placental samples from healthy and preeclamptic pregnancies were collected at 
elective caesarean delivery.  
5.3.3   Tissue Explant (Kisspeptin Stimulation) Experiments
Fresh placental tissue samples were washed with PBS and collected on ice. The 
placental tissue (50mg) was equally apportioned for various time points in tissue 
culture 9-well plates and kept in a humidified incubator at 37oC and 5% CO2. Placental 
tissue explants were still viable after 24hrs of incubation. The samples were treated 
with either vehicle (DMEM F12 medium) or vehicle plus kisspeptin (100nM) at each 
time point (8, 12 and 24hours). After each time point had elapsed, the media was 
suctioned off from the 9-well plates and 1ml TRIzol® reagent was added to the tissue 
for RNA extraction purposes. For the zero (0) hour time point, TRIzol® reagent was 
immediately added instead of medium. 
5.3.4   RNA Extraction 
1ml Trizol was used per 50mg of placental tissue for lysis. Tissue was homogenised 
on ice with a Tissue Ruptor® (Qiagen). The homogenate was centrifuged at 15000g at 
40C for 15minutes and 200ml of ice-cold BCP (Sigma) was added to the supernatant. 
The mixture was shaken for 15seconds and kept on ice for 10mins. The solution was 
again centrifuged and the top aqueous phase was removed and transferred to a new 
tube.  This was followed by addition of 500ml of propanol and the tube was again 
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centrifuged to precipitate RNA. RNA pellets were washed in 75% ethanol, air dried 
and re-suspended in DEPC-treated water. 
5.3.5   cDNA Synthesis
RNA was reverse transcribed with Multiscribe Reverse Transcription reagents (Applied 
Biosystems). DEPC-treated H2O (3.7ml), 10x RT Buffer (2ml), MgCl2 (4.4ml), dNTPs (4ml), 
Random Hexamers(1ml), RNAse Inhibitor (0.4ml), Reverse Transcriptase (0.5ml) and 
(2ml) of RNA were utilized for a 20ml reverse transcription reaction. The ABI GeneAmp® 
2700 Thermal Cycler was programmed for the following reaction steps:  250C (10 
mins), 40C (10 mins), 480C (45 mins) and 950C (5 mins).
5.3.6   Real-Time PCR
The ABI 7900 RT-qPCR instrument (Applied Biosystems) was utilized to perform gene 
expression studies. The standard thermal cycling protocol was conducted as follows: 
500C for 2mins, 950C for 10mins and 40 cycles of (950C for 95secs and 600C for 1min). 
The Genebank accession numbers of the genes investigated are as follows: VEGF-A 
(NM_001171623), VEGFR-1(NM_ 002019) and VEGFR-2 (NM_002253). Primer/Probe 
pairs corresponding to these genes (Sigma® Pharmaceuticals) were utilised (Table 
I) in the presence of the Taqman® Mastermix. All RT-qPCR gene expression data is 
presented as Means ± SEM and expression is relative to 18S ribosomal RNA (internal 
control) and reference cDNA.
5.4   Statistical Analysis
Repeated measures two-way ANOVA was employed to compare placental mRNA 
transcript expression at various time points between healthy and preeclamptic 
pregnancies. The statistical package utilized was GraphPad Prism version 5.00 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. 
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Statistical significance was set at p < 0.05. 
5.5   Results
5.5.1   The effect of kisspeptin-10 stimulation on placental VEGF-A 
transcript expression.
In healthy pregnancies an increase in the basal placental VEGF-A mRNA expression at 
8 and 12hours was observed which reverted to baseline levels at 24hours. Kisspeptin 
stimulation resulted in a modest reduction in placental VEGF-A mRNA expression at 8 
and 12hours but this did not reach statistical significance. In preeclamptic pregnancies 
the basal placental VEGF-A mRNA expression levels were comparable through all 
time-points with a non-significant increase at 8hours following kisspeptin stimulation 
(Figure 5.1).
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Figure 5.1.  The effect of kisspeptin-10 stimulation on VEGF-A mRNA expression in healthy 
and preeclamptic placental tissue. Relative VEGF-A mRNA expression following healthy (A) and 
preeclamptic (B) placental explant incubation with 100nM kisspeptin-10 for 8, 12 and 24 hour 
durations. Pv (blue and red bars) represents placental stimulation with vehicle (DMEM-F12 medium) 
while Pkp (yellow) signifies placental stimulation with 100nM kisspeptin-10. mRNA expression was 
quantified relative to 18S RNA and control cDNA by RT-PCR. 
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5.5.2   The effect of kisspeptin-10 stimulation on placental VEGFR-1    
transcript expression
In healthy pregnancies, basal VEGFR-1 mRNA expression was comparable at all time 
points with a consistent non-significant suppression following kisspeptin stimulation. 
Similarly in preeclamptic placentae, the basal VEGFR-1 mRNA expression was 
consistent and kisspeptin stimulation had a non-significant increase in VEGFR-1 
transcript expression over time (Figure 5.2). Thus, kisspeptin had no effect on VEGFR-1 
mRNA expression in both healthy and preeclamptic pregnancies.
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Figure 5.2.  The  effect of kisspeptin-10 stimulation on VEGFR-1  mRNA expression in 
healthy and preeclamptic placental tissue. Relative VEGFR-1 mRNA expression following 
incubation of healthy (A) and preeclamptic (B) placental explants with 100nM kisspeptin-10 for 
8, 12 and 24 hour periods. Pv (blue and red bars) represents placental stimulation with vehicle 
(DMEM-F12 medium) while Pkp (yellow) signifies placental stimulation with 100nM kisspeptin-
10. mRNA expression was quantified relative to 18S RNA and control cDNA by RT-PCR.  
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18S RNA and control cDNA by RT-PCR. 
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5.5.3   The effect of kisspeptin-10 stimulation on placental VEGFR-2 
transcript expression.
Kisspeptin  had no effect on  VEGFR-2 expression in both healthy and preeclamptic 
pregnancies (Figure 5.3)
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Figure 5.3  The  effect of kisspeptin-10 stimulation on VEGFR-2  mRNA expression in 
healthy and preeclamptic placental tissue. Figure 5.3 represents relative VEGFR-2 mRNA 
expression following incubation of healthy (A) and preeclamptic (B) placental explants with 
100nM kisspeptin-10 for 8, 12 and 24 hour periods. Pv (blue and red bars) represents placental 
stimulation with vehicle (DMEM-F12 medium) while Pkp (yellow) signifies placental stimulation 
with 100nM kisspeptin-10. mRNA expression was quantified relative to 18S RNA and control 
cDNA by real-time reverse transcriptase polymerase chain reaction (RT-PCR). 
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explants with 100nM kisspeptin-10 for 8, 12 and 24 hour periods. Pv (blue and red 
bars) represents placental stimulation with vehicle (DMEM-F12 medium) while Pkp 
(yellow) signifies placental stimulation with 100nM kisspeptin-10. mRNA expression 
was quantified relative to 18S RNA and control cDNA by real-time reverse transcriptase 
polymerase chain reaction (RT-PCR).
5.6   Discussion 
This study examined the response of healthy and preeclamptic placental tissue to 
stimulation with kisspeptin-10 over a 24 hour time course. In particular we investigated 
the effect of kisspeptin-10 on mRNA expression of angiogenic ligand VEGF-A and its 
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receptors (VEGFR-1 and VEGFR-2) in these tissues. Kisspeptin had no effect on the 
mRNA expression of VEGF-A, VEGFR-1 or VEGFR-2.
Suppression of VEGF-A mRNA (Francis et al., 2014) and angiogenesis (Ramaesh et 
al., 2010) by kisspeptin-10 in first trimester placental tissue has been reported and 
is likely one mechanism involved in inhibition of trophoblast invasion and tumour 
metastasis. In Chapter three we postulated that VEGF-A is likely more involved in 
maternal rather than placental angiogenesis in healthy pregnancies while in Chapter 
4 placental VEGF-A mRNA expression was suppressed in pregnancies complicated 
by preeclampsia (Figure 4.5). Furthermore, placental  kisspeptin-10 expression was 
elevated in preeclampsia when compared to healthy pregnancies (Figure 4.2). Hence 
the failure of kisspeptin-10 to have any effect on the mRNA expression of VEGF-A 
and its receptors might be explained by the already elevated placental expression 
of kisspeptin in healthy and more so in preeclamptic placentae. If this is the case 
then suppression of endogenous kisspeptin expression in the placenta with recently 
described kisspeptin antagonists (Roseweir et al., 2009) prior to stimulation with 
kisspeptin could be attempted in the future.
It still remains of interest what the effect of kisspeptin on angiogenic events in the 
maternal placental bed and decidua parietalis would be. There is always sufficient 
placental tissue  available to conduct stimulation experiments however the amount 
of placental bed and decidua parietalis is usually limited. This restricted the ability to 
conduct these experiments on maternal tissue.
VEGFR-1 antagonises VEGF-A and is normally produced in large quantities by 
the placenta (Clark et al., 1998a). The soluble form of VEGFR-1 (sFLT-1) has been 
consistently found to be elevated in the circulation and placentae of preeclamptic 
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patients (Levine et al., 2004, Luttun and Carmeliet, 2003, Maynard et al., 2003, 
Sitras et al., 2009, Munaut et al., 2012). Furthermore, introduction of the sFLT-1 gene 
induces a preeclampsia-like phenotype in pregnant Sprague-Dawley rats (Maynard 
et al., 2003). Kisspeptin-10 stimulation resulted in a trend towards suppression of 
placental VEGFR-1 expression in healthy pregnancies and an elevated expression in 
preeclampsia. This raises the question of whether the elevated expression of VEGFR-1 
in preeclamptic placentae could be kisspeptin driven.
Unlike VEGFR-1 which antagonises VEGF-A, VEGFR-2 mediates the angiogenic 
and mitogenic effects of VEGF-A, and is the key angiogenic receptor. Kisspeptin 
stimulation had no effect on placental VEGFR-2 mRNA expression. Recently, a study 
examining placental and circulatory VEGFR-1 and VEGFR-2 mRNA in preeclampsia 
reported lower VEGFR-2 in the circulation of preeclamptic patients (Munaut et al., 
2012). Furthermore the levels of soluble VEGFR-1 in circulation decreased post-
delivery in keeping with its placental origin whereas that of VEGFR-2 persisted albeit 
at lower levels, suggesting a maternal endothelial origin of the peptide. 
In the previous chapter we demonstrated suppressed angiogenic ligand expression 
(EG-VEGF in the placentae and decreased VEGF-A in the placental beds) of pregnancies 
complicated by preeclampsia. The observed trend of elevated angiogenic VEGF-A 
expression in preeclamptic placentae in response to kisspeptin stimulation may 
be a compensatory mechanism to suppressed placental (EG-VEGF mediated) and 
placental bed (VEGF-A mediated) angiogenesis. The suppressed VEGF-A expression 
in the placental beds of preeclamptic pregnancies reported in most studies (Table 4.3) 
may be secondary to elevated placental VEGFR-1 expression which may in part be 
kisspeptin driven.
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A concession has to be made that these are observed trends rather than statistically 
significant effects. As kisspetin is abundantly expressed in pregnancy (Horikoshi, 
2003), future work should involve suppression of endogenous kisspeptin with 
kisspeptin antagonists prior to stimulation experiments as this may further elaborate 
the tissue responses. 
Chronic exposure to kisspeptin triggers the desensitization of GPR-54. In the 
placenta, there is high concentrations of kisspeptin that increase during trimester the 
first trimester, therefore chronic exposure to GPR-54 actually reflects a physiological 
situation.  The net outcome is an integration between receptor de-sensitization and 
re-sensitization.
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6.1   DISCUSSION 
Pregnancy-related disorders contribute significantly to global maternal and perinatal 
morbidity and mortality. To have an impact on pregnancy-related pathology requires 
a comprehensive understanding of the molecular processes involved in placentation 
and subsequent maternal-fetal dialogue in pregnancy health. In this dissertation the 
role that kisspeptin, encoded by the Kiss-1 gene and signalling via its receptor GPR-
54, plays in placentation is investigated. In particular its expression along with that 
of angiogenic ligand and receptors at gene and protein levels is explored across the 
maternal-fetal interface of pregnancy health and pathology. Lastly, its role on the 
transcript expression of angiogenic ligand VEGF-A and its receptors is examined. 
6.1.1   The role of kisspeptin in pregnancy health
The expression of kisspeptin and GPR-54 had previously been reported in human 
first trimester trophoblasts (Bilban et al., 2004, Park et al., 2012, Qiao et al., 2005a), 
placenta (Cartwright and Williams, 2012, Qiao et al., 2012, Qiao et al., 2005b, Ramaesh 
et al., 2010, Zhang et al., 2006, Zhang et al., 2011) and trophoblast cell-lines (Roseweir 
et al., 2012, Zhang et al., 2011). Their expression had never been investigated 
across maternal-fetal tissues, in particular the maternal placental bed and decidua 
parietalis. This study found high Kiss-1 and GPR-54 mRNA expression in the placenta 
in comparison to the placental bed and decidua parietalis. Immunohistochemistry 
detected neither protein in the maternal tissues (Matjila et al., 2013). Similar to others 
(Bilban et al., 2004), it was found that the expression of kisspeptin was restricted to 
the syncytiotrophoblast while that of its receptor was localized to the villous syncytio- 
and cytotrophoblasts as well as extravillous cytotrophoblast columns. Kisspeptins 
inhibit trophoblast migration and invasion and likely play an invasive trophoblast auto-
regulatory role across the maternal-fetal interface from the first trimester to term in 
healthy pregnancies. 
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In healthy pregnancies decreased VEGF-A mRNA and protein in the placenta in 
comparison to the placental bed which had highest expression across the maternal-
fetal interface was observed. At the same time, the mRNA expression of both PROK-1 
and its receptor (PROK-1R) were expressed highest in the placenta when compared 
to the placental bed and decidua parietalis. Altogether these findings suggest 
that VEGF-A is unlikely to be the dominant factor mediating angiogenesis in the 
placenta and that kisspeptin may play a role in its placental suppression in favour of 
prokineticin-mediated angiogenesis. It is now known that prokineticin-1 plays a key 
role in endometrial receptivity, regulation of implantation-related genes and placental 
angiogenesis (Evans et al., 2008, Hoffmann et al., 2006, Brouillet et al., 2010, Salker 
et al., 2010).
6.1.2   The role of kisspeptin in the preeclampsia
Due to its effects on tumour metastasis suppression and inhibition of trophoblast 
migration and invasion, the role of kisspeptin has naturally generated interest in 
preeclampsia research, whose underlying pathophysiology involves limited invasion of 
trophoblast and inadequate transformation of spiral arteries. The expression of Kiss-1 
transcript and protein was investigated across the maternal-fetal tissues (placenta, 
placental bed and decidua parietalis) of healthy and preeclamptic pregnancies. In 
addition, circulatory kisspeptin-10 levels in maternal and cord sera of healthy and 
preeclamptic pregnancies were explored. Elevated expression of kisspeptin-10 was 
found in the placentae of preeclamptic pregnancies along with suppressed mean 
maternal kisspeptin-10 levels in circulation. Although Kiss-1 mRNA was modestly 
higher in the preeclamptic placentae, there was no difference in placental bed and 
decidua parietalis. Kiss-1 mRNA expression between healthy pregnancies and 
preeclampsia. Most studies have reported elevated expression of Kiss-1 mRNA and 
protein in trophoblast (Qiao et al., 2005b) and placentae of preeclamptic pregnancies 
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(Qiao et al., 2012, Zhang et al., 2006, Zhang et al., 2011). Only one study recently 
found decreased placental Kiss-1 mRNA and protein expression along with increased 
placental Kiss-1R (GPR-54) in preeclampsia (Cartwright and Williams, 2012). The 
current study and others (Qiao et al., 2012) found no difference in placental GPR-54 
expression between healthy and preeclamptic pregnancies, in addition this research 
reports no difference in placental bed and decidua parietalis GPR-54 receptor 
expression between pregnancy health and preeclampsia. The elevated placental Kiss-1 
expression in preeclampsia is in keeping with the currently accepted pathophysiology 
of the condition.
This study  shows that kisspeptin stimulation resulted in a trend towards suppression 
of placental VEGF-A expression in healthy pregnancies. In a separate study our group 
recently demonstrated that kisspeptin suppresses VEGF-A mRNA expression in primary 
human trophoblast cells isolated from first trimester terminations (Francis et al., 2014). 
The current study also demonstrated significant suppression of angiogenic factor 
transcript expression across the maternal-fetal interface of pregnancies complicated 
by preeclampsia, with VEGF-A suppressed in the placental bed and PROK-1 in the 
placenta. (Fig 6.1). As others have demonstrated that kisspeptin suppresses both 
VEGF-A  expression (Cho et al., 2009) and angiogenesis (Ramaesh et al., 2010), it is 
likely that elevated placental kisspeptin expression results in suppressed placental 
bed VEGF-A expression and compromised angiogenesis in the maternal spiral arteries 
of pregnancies complicated by preeclampsia. 
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Figure 6.1 The schematic of putative interaction at the maternal-fetal interface 
of healthy and preeclamptic pregnancies. This figure illustrates increased kisspeptin 
expression (green) in the syncytitiotrophoblast layer of preeclamptic placenta. This 
leads to reduced  cytotrophoblast column formation and EVT populations (pink 
cells). The consequence is less interstitial and endovascular trophoblast invasion and 
transformation of decidual (DSA) and myometrial (MSA) components of spiral arteries in 
the decidua basalis and junctional zone myometrium. Reduced interstitial trophoblast 
populations in preeclampsia also translates to less interaction between trophoblast 
and immune cellular components in the decidua basalis such as decidual lymphocytes 
and UNK cells. This may limit production of cytokines and factors that favour immune 
tolerance leading to compromised trophoblast-independent transformation of maternal 
spiral arteries. Increased kisspeptin likely results in suppressed VEGF-A expression in 
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the placental bed further compromising spiral arterial transformation in preclampsia.
In healthy pregnancies the maternal and cord serum kisspeptin-10 levels were 
comparable but in preeclamptic pregnancies maternal concentrations were 
significantly lower than cord levels. Furthermore circulatory kisspeptin-10 levels 
in preeclampsia were significantly lower than those in healthy pregnancies. Hence 
despite elevated tissue kisspeptin-10 expression levels in preeclampsia, mean 
circulatory concentrations were much lower when compared to healthy pregnancies. 
Several studies have demonstrated the association between low circulating kisspeptin 
levels and other pregnancy-related pathology including preeclampsia (Armstrong et 
al., 2009, Cetkovic et al., 2012, Kavvasoglu et al., 2012, Smets et al., 2008). This 
is just another instance exemplifying that peripheral circulatory measurements are 
not necessarily reflective of tissue expression. It can be postulated that decreased 
circulating kisspeptin levels in preeclampsia or pregnancy-related pathology may be 
a consequence of compromised endovascular invasion resulting in a reduced amount 
of kisspeptin-secreting trophoblast cells in the maternal spiral arteries. There is 
therefore a potential to utilize diminished kisspeptin levels in the maternal circulation 
as a surrogate for placental dysfunction (Cetkovic et al., 2012). 
6.2   Conclusion 
Placentation is a key process to understand as it directly determines pregnancy 
outcome. More crucial to comprehend are molecular events in the maternal-fetal 
interface. This work describes the expression of Kiss-1, kisspeptin, its receptor GPR-
54 and angiogenic factors (which are crucial in placentation) across the maternal-fetal 
tissues, first in pregnancy health, and their subsequent derangement in preeclampsia. 
The study defines for the first time the expression of Kiss-1 and GPR-54 as well 
as that of recently described angiogenic factor PROK-1 and its receptor PROK-1R 
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across maternal-fetal tissues. In particular their expression in the maternal placental 
bed which is the primary site of maternal-fetal interaction and transformation of 
spiral arteries is described. Basal angiogenic factor expression across maternal-fetal 
tissues was suggestive of PROK-1/PROK-1R ligand-receptor pair as key role players 
in placental angiogenesis while VEGF-A/VEGFR-2 likely mediated angiogenesis in the 
maternal placental bed. Preeclamptic pregnancies were characterised by significant 
angiogenic factor suppression with decreased  PROK-1 and VEGF-A expression  in 
the placenta and placental bed respectively.  The most remarkable suppression was 
that of VEGF-A in the placental bed and this has been a consistent finding of the 
few studies examining placental bed VEGF-A expression in preeclampsia. Stimulation 
of placental tissue from healthy and preeclamptic pregnancies showed no effect of 
kisspeptin-10 on VEGF-A, VEGFR-1 or VEGFR-2 mRNA expression however this could 
have been due to high endogenous kisspeptin expression in placental tissue. Lastly 
this study shows for the first time that while placental kisspeptin-10 expression is 
elevated in preeclampsia, peripheral circulatory concentrations are suppressed. This 
finding, along with supportive data from other studies demonstrating low circulating 
kisspeptin levels in pregnancy-related pathology, introduces the possibility of utilizing 
diminished circulatory kisspeptin concentrations as a surrogate marker of placental 
dysfunction.
6.3   Future Studies 
The differential role of kisspeptin in healthy and preeclamptic pregnancies needs 
further exploration. Pre-treatment with kisspeptin antagonists to suppress endogenous 
kisspeptin levels will be crucial in these experiments. The effects of kisspeptin on 
placental and decidual components from healthy and other pathological pregnancies 
(e.g. intrauterine growth restriction and recurrent miscarriage) sharing the same 
pathophysiology as preeclampsia should be investigated. The effect of kisspeptin 
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on the placental angiogenic factor PROK-1 and its signalling pathways needs further 
study together with kisspeptin-mediated epigenetic changes in pregnancy. 
Lastly, in vivo studies conducted in an animal model reflective of deep placentation 
as is the case in human pregnancy, needs to be utilized to further explore the role of 
kisspeptin in maternal-fetal dialogue and angiogenesis.
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BUFFERS AND SOLUTIONS
 
RIPA Buffer 
25mM Tris HCl pH 7.6
150mM NaCl
1% Triton X
1% Sodium deoxycholate
0.1% SDSLaemmli Buffer
Laemmli Buffer
125mM Tris-HCl pH 6.8
4% SDS
20% Glycerol 
5% 2-mercapthoethanol
0.05% bromophenol blue 
Lysis Buffer 
150mM NaCl
10% Glycerol 
0.6% (v/v) NP-40
50mM Tris HCl pH 7.4
10mM EDTA (add protease cocktail inhibitor tablet before use)
10x Phosphate-Buffered Saline (PBS)
80g NaCl
2g KCl
14.4g Na2HPO4
2.4g KH2PO4
800ml distilled H2O, pH adjusted to 7.4 to a final volume of 1L.
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SDS-PAGE Stacking and Resolving Gels
30%  Acrylamide
1.5M Tris (pH 6.8) Stacking Gel / (pH 8.8) Resolving Gel
10% SDS
Distilled H2O
TEMED
10% APS
10x Tris-Buffered Saline (TBS)
80g NaCl
2g KCl
30g Tris Base
800ml distilled H2O, pH adjusted to 7.4 to a final volume of 1L.
1x TBST (1L)
100ml (10x) TBS 
900ml distilled H2O
1ml Tween 20®
Transfer Buffer
25mM Tris HCl
0.192M Glycine
20% Methanol
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